navan
/
Daily-Dose
mirror of https://github.com/navanchauhan/Daily-Dose.git
1
0
Fork 0
Code Issues Projects Releases Wiki Activity

Added daily report

This commit is contained in:
Navan Chauhan 2021-01-06 13:00:58 +00:00
parent 9a57f7a0aa
commit ba2d966b28
3 changed files with 787 additions and 2 deletions
Show Stats Download Patch File Download Diff File Expand all files Collapse all files

184
archive-covid-19/06 January, 2021.html Normal file
View File

@ -0,0 +1,184 @@
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"><head>
<meta content="text/html; charset=utf-8" http-equiv="Content-Type"/>
<meta content="text/css" http-equiv="Content-Style-Type"/>
<meta content="pandoc" name="generator"/>
<title></title>
<style type="text/css">code{white-space: pre;}</style>
<title>Covid-19 Sentry</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
<body>
<h1 data-aos="fade-down" id="covid-19-sentry">Covid-19 Sentry</h1>
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
<ul>
<li><a href="#from-preprints">From Preprints</a></li>
<li><a href="#from-clinical-trials">From Clinical Trials</a></li>
<li><a href="#from-pubmed">From PubMed</a></li>
<li><a href="#from-patent-search">From Patent Search</a></li>
</ul>
<h1 data-aos="fade-right" id="from-preprints">From Preprints</h1>
<ul>
<li><strong>Possible hospital acquired Acinetobacter, Klebsiella, Mycoplasma and Legionella secondary infections in Covid19 patients from Russia</strong> -
<div>
The hypothesis that SARS-Cov2 enables anaerobic bacteria to colonize the lungs disrupting homeostasis, causing long-drawn chronic symptoms, and acute severe symptoms (ARDS, septic shock, clots, arterial stroke) which finds resonance, with key differences, in the ‘forgotten disease’ Lemierre Syndrome [1], enabled by Epstein Barr Virus [2] has found corroboration in other studies. An assessment of immunity in mild versus severe COVID-19 infection in humans found that severity correlated with increased bacterial products in plasma [3], while another study reported endotoxemia and circulating bacteriome in severe COVID-19 patients [4]. Fusobacterium nucleatum bacteremia was reported in Covid19 patients in Belgium [5]. The overlapping symptoms can often confuse diagnosis [6, 7]. ‘Jugular vein distention’ should have led to a Lemierre like diagnosis [8]. While, these are commensal lung microbiome, hospital acquired infections (HAI) also play a major role in fatal outcomes for Covid19 patients. Acinetobacter/Legionella/Mycoplasma/Klebsiella possible co-infections in Covid19 patients from Russia (Accid:PRJNA682735). Some of these samples have no SARS-Cov2 reads - these could be control samples. The viral load is quite low in many patients, indicating that these might lead to false negative results [9]. It is interesting to note that samples with higher viral load also have higher % of anaerobic bacteria.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://osf.io/jzcrf/" target="_blank">Possible hospital acquired Acinetobacter, Klebsiella, Mycoplasma and Legionella secondary infections in Covid19 patients from Russia</a>
</div></li>
<li><strong>Increased air pollution exposure among the Chinese population during the national quarantine in 2020</strong> -
<div>
The COVID-19 quarantine in China is thought to have been beneficial for reducing the population exposure to ambient air pollution. The overall exposure also depends, however, on indoor air quality and human mobility and activities, which also changed during the pandemic. Here we integrate real-time mobility data, questionnaire survey on during-pandemic human activity patterns, advanced air quality modeling techniques, and an indoor exposure model. We first show a decrease of 16.7 μg∙m-3 in the national average population-weighted ambient PM2.5 during the quarantine (i.e., the one month following the start of the Spring Festival holiday). The total population-weighted exposure (PWE) to PM2.5 considering both indoor and outdoor environments, however, increased by 5.7 μg∙m-3. The increase in PWE was mainly due to the nationwide population migration from urban to rural areas before the Spring Festival coupled with the freezing of the migration backward due to the quarantine (+10.8 μg∙m-3), which increased household energy consumption and the fraction of people exposed to rural household air pollution (HAP) indoors. The changes in PWE due to the quarantine were -14.0 and +19.2 ug∙m-3 among urban and rural populations, respectively, and ranged from -9.1 ug∙m-3 in the provinces with the highest per-capita income to 7.1 ug∙m-3 in the provinces with the lowest. HAP contributed 82% of PWE during this period, which was likely more severe than any period in recent years. Our analysis reveals an increased inequality of air pollution exposure during the COVID-19 quarantine and highlights the importance of HAP for population health in China.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://osf.io/preprints/eartharxiv/6d9rn/" target="_blank">Increased air pollution exposure among the Chinese population during the national quarantine in 2020</a>
</div></li>
<li><strong>Evidence For COVID-19 Vaccine Deferred Dose 2 Boost Timing</strong> -
<div>
Both Pfizer and Moderna vaccine trials used accelerated methods to achieve rapid FDA approval with minimal and wise compromises. While many established vaccines use boost / dose 2 timings that are typically in the 3 to 120 months range , dose 2 timings for both trials were less than 30 days as part of a crucial effort to rapidly develop a vaccine with significant efficacy. Data from both trials showed excellent dose 1 efficacy; however, neither of the related Safety and Efficacy publications highlighted this dose 1 efficacy excellence. The trials, manufacturing, and distribution programs have rapidly delivered millions of doses to points of care. However, the ability to administer these doses at localities as rapidly as they can be distributed has been shown as the largest current challenge to achieving the widespread vaccination. Improvements could reduce mortality rates that presently exceed 2000 per day, avoid serious cases at a time where hospital census is at full capacity or beyond, and minimize long-term sequelae. This study suggests that it is possible to achieve these and other goals by recognizing the evidence for COVID-19 vaccine deferred boost timing and using a more conventional, decades-tested, boost timing on the order of months. This would enable currently limited US resources to effectively double the population being vaccinated over the next few months, enabling more rapid vaccination of those at highest-risk for severe infections.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://osf.io/4p3bt/" target="_blank">Evidence For COVID-19 Vaccine Deferred Dose 2 Boost Timing</a>
</div></li>
<li><strong>In-Vitro Fluorescence Microscopy Studies Show Retention of Spike-Protein (SARS-Cov-2) on Cell Membrane in the Presence of Amodiaquin Dihydrochloride Dihydrate Drug</strong> -
<div>
The ability of S-glycoprotein (S-protein) in SARS-Cov-2 to bind to the host cell receptor protein (angiotensinconverting enzyme 2 (ACE2)) leading to its entry in cellular system determines its contagious index and global spread. Three available drugs (Riboflavin, Amodiaquin dihydrochloride dihydrate (ADD) and Remidesivir) were investigated to understand the kinetics of S-protein and its entry inside a cellular environment. Optical microscopy and fluorescence-based assays on 293T cells (transfected with ACE2 plasmid) were used as the preamble for assessing the behaviour of S-protein in the presence of these drugs for the first 12 hours post S-protein - ACE2 binding. Preliminary results suggest relatively long retention of S-protein on the cell membrane in the presence of ADD drug. Evident from the %-overlap and colocalization of S-protein with endosome studies, a large fraction of S-protein entering the cell escape endosomal degradation process, suggesting S-protein takes non-endocytic mediated entry in the presence of ADD, whereas in the presence of Riboflavin, S-protein carry out normal endocytic pathway, comparable to control (no drug) group. Therefore, present study indicates ADD potentially affects S-protein's entry mechanism (endocytic pathway) in addition to its reported target action mechanism. Hence, ADD substantially interfere with S-protein cellular entrance mechanism. However, further detailed studies at molecular scale will clarify our understanding of exact intermediate molecular processes. The present study (based on limited data) reveal ADD could be potential candidate to manage Covid-19 functions through yet unknown molecular mechanism.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.01.05.424956v1" target="_blank">In-Vitro Fluorescence Microscopy Studies Show Retention of Spike-Protein (SARS-Cov-2) on Cell Membrane in the Presence of Amodiaquin Dihydrochloride Dihydrate Drug</a>
</div></li>
<li><strong>Molecular Mechanism of the N501Y Mutation for Enhanced Binding between SARS-CoV-2's Spike Protein and Human ACE2 Receptor</strong> -
<div>
Coronavirus disease 2019 (COVID-19) has been an ongoing global pandemic for over one year. Recently, an emergent SARS-CoV-2 variant (B.1.1.7) with an unusually large number of mutations had become highly contagious and wide-spreading in United Kingdom. From genome analysis, the N501Y mutation within the receptor binding domain (RBD) of the SARS-CoV-2's spike protein might have enhanced the viral protein's binding with the human angiotensin converting enzyme 2 (hACE2). The latter is the prelude for the virus' entry into host cells. So far, the molecular mechanism of this enhanced binding is still elusive, which prevents us from assessing its effects on existing therapeutic antibodies. Using all atom molecular dynamics simulations, we demonstrated that Y501 in mutated RBD can be well coordinated by Y41 and K353 in hACE2 through hydrophobic interactions, increasing the overall binding affinity between RBD and hACE2 by about 0.81 kcal/mol. We further explored how the N501Y mutation might affect the binding between a neutralizing antibody (CB6) and RBD. We expect that our work can help researchers design proper measures responding to this urgent virus mutation, such as adding a modified/new neutralizing antibody specifically targeting at this variant in the therapeutic antibody cocktail.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.01.04.425316v1" target="_blank">Molecular Mechanism of the N501Y Mutation for Enhanced Binding between SARS-CoV-2's Spike Protein and Human ACE2 Receptor</a>
</div></li>
<li><strong>Ipomoeassin-F inhibits the in vitro biogenesis of the SARS-CoV-2 spike protein and its host cell membrane receptor</strong> -
<div>
In order to produce proteins essential for their propagation, many pathogenic human viruses, including SARS-CoV-2 the causative agent of COVID-19 respiratory disease, commandeer host biosynthetic machineries and mechanisms. Three major structural proteins, the spike, envelope and membrane proteins, are amongst several SARS-CoV-2 components synthesised at the endoplasmic reticulum (ER) of infected human cells prior to the assembly of new viral particles. Hence, the inhibition of membrane protein synthesis at the ER is an attractive strategy for reducing the pathogenicity of SARS-CoV-2 and other obligate viral pathogens. Using an in vitro system, we demonstrate that the small molecule inhibitor ipomoeassin F (Ipom-F) potently blocks the Sec61-mediated ER membrane translocation/insertion of three therapeutic protein targets for SARS-CoV-2 infection; the viral spike and ORF8 proteins together with angiotensin-converting enzyme 2, the host cell plasma membrane receptor. Our findings highlight the potential for using ER protein translocation inhibitors such as Ipom-F as host-targeting, broad-spectrum, antiviral agents.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2020.11.24.390039v2" target="_blank">Ipomoeassin-F inhibits the in vitro biogenesis of the SARS-CoV-2 spike protein and its host cell membrane receptor</a>
</div></li>
<li><strong>Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice</strong> -
<div>
Protection against SARS-CoV-2 and SARS-related emergent zoonotic coronaviruses is urgently needed. We made homotypic nanoparticles displaying the receptor-binding domain (RBD) of SARS-CoV-2 or co-displaying SARS-CoV-2 RBD along with RBDs from animal betacoronaviruses that represent threats to humans (mosaic nanoparticles; 4-8 distinct RBDs). Mice immunized with RBD-nanoparticles, but not soluble antigen, elicited cross-reactive binding and neutralization responses. Mosaic-RBD-nanoparticles elicited antibodies with superior cross-reactive recognition of heterologous RBDs compared to sera from immunizations with homotypic SARS-CoV-2-RBD-nanoparticles or COVID-19 convalescent human plasmas. Moreover, sera from mosaic-RBD-immunized mice neutralized heterologous pseudotyped coronaviruses equivalently or better after priming than sera from homotypic SARS-CoV-2-RBD-nanoparticle immunizations, demonstrating no immunogenicity loss against particular RBDs resulting from co-display. A single immunization with mosaic-RBD-nanoparticles provides a potential strategy to simultaneously protect against SARS-CoV-2 and emerging zoonotic coronaviruses.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2020.11.17.387092v3" target="_blank">Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice</a>
</div></li>
<li><strong>Structural Genetics of circulating variants affecting the SARS CoV-2 Spike / human ACE2 complex</strong> -
<div>
SARS-CoV-2 entry in human cells is mediated by the interaction between the viral Spike protein and the human ACE2 receptor. This mechanism evolved from the ancestor bat coronavirus and is currently one of the main targets for antiviral strategies. However, there currently exist several Spike protein variants in the SARS-CoV-2 population as the result of mutations, and it is unclear if these variants may exert a specific effect on the affinity with ACE2 which, in turn, is also characterized by multiple alleles in the human population. In the current study, the GBPM analysis, originally developed for highlighting host-guest interaction features, has been applied to define the key amino acids responsible for the Spike/ACE2 molecular recognition, using four different crystallographic structures. Then, we intersected these structural results with the current mutational status, based on more than 295,000 sequenced cases, in the SARS-CoV-2 population. We identified several Spike mutations interacting with ACE2 and mutated in at least 20 distinct patients: S477N, N439K, N501Y, Y453F, E484K, K417N, S477I and G476S. Among these, mutation N501Y in particular is one of the events characterizing SARS-CoV-2 lineage B.1.1.7, which has recently risen in frequency in Europe. We also identified five ACE2 rare variants that may affect interaction with Spike and susceptibility to infection: S19P, E37K, M82I, E329G and G352V.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2020.09.09.289074v3" target="_blank">Structural Genetics of circulating variants affecting the SARS CoV-2 Spike / human ACE2 complex</a>
</div></li>
<li><strong>Rejuveinix Mitigates Sepsis-Associated Oxidative Stress in the Brain of Mice: Clinical Impact Potential in COVID-19 and Nervous System Disorders</strong> -
<div>
Here, we demonstrate that our anti-sepsis and COVID-19 drug candidate Rejuveinix (RJX) substantially improves the survival outcome in the LPS-GalN animal model of sepsis and multi-organ failure. One hundred (100) percent (%) of untreated control mice remained alive throughout the experiment. By comparison, 100% of LPS-GalN injected mice died at a median of 4.6 hours. In contrast to the invariably fatal treatment outcome of vehicle-treated control mice, 40% of mice treated with RJX (n=25) remained alive with a 2.4-fold longer median time survival time of 10.9 hours (Log-rank X2=20.60, P&lt;0.0001). Notably, RJX increased the tissue levels of antioxidant enzymes SOD, CAT, and GSH-Px, and reduced oxidative stress in the brain. These findings demonstrate the clinical impact potential of RJX as a neuroprotective COVID-19 and sepsis drug candidate.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.01.03.424883v1" target="_blank">Rejuveinix Mitigates Sepsis-Associated Oxidative Stress in the Brain of Mice: Clinical Impact Potential in COVID-19 and Nervous System Disorders</a>
</div></li>
<li><strong>Hydroxyzine inhibits SARS-CoV-2 Spike protein binding to ACE2 in a qualitative in vitro assay</strong> -
<div>
COVID-19 currently represents a major public health problem. Multiple efforts are being performed to control this disease. Vaccinations are already in progress. However, no effective treatments have been found so far. The disease is caused by the SARS-CoV-2 coronavirus that through the Spike protein interacts with its cell surface receptor ACE2 to enter into the host cells. Therefore, compounds able to block this interaction may help to stop disease progression. In this study, we have analyzed the effect of compounds reported to interact and modify the activity of ACE2 on the binding of the Spike protein. Among the compounds tested, we found that hydroxyzine could inhibit the binding of the receptor-binding domain of Spike protein to ACE2 in a qualitative in vitro assay. This finding supports the reported clinical data showing the benefits of hydroxyzine on COVID-19 patients, raising the need for further investigation into its effectiveness in the treatment of COVID-19 given its well-characterized medical properties and affordable cost.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.01.04.424792v1" target="_blank">Hydroxyzine inhibits SARS-CoV-2 Spike protein binding to ACE2 in a qualitative in vitro assay</a>
</div></li>
<li><strong>Immunogenicity of an AAV-based, room-temperature stable, single dose COVID-19 vaccine in mice and non-human primates</strong> -
<div>
The SARS-CoV-2 pandemic has affected more than 70 million people worldwide and resulted in over 1.5 million deaths. A broad deployment of effective immunization campaigns to achieve population immunity at global scale will depend on the biological and logistical attributes of the vaccine. Here, two adeno-associated viral (AAV)-based vaccine candidates demonstrate potent immunogenicity in mouse and nonhuman primates following a single injection. Peak neutralizing antibody titers remain sustained at 5 months and are complemented by functional memory T-cells responses. The AAVrh32.33 capsid of the AAVCOVID vaccine is an engineered AAV to which no relevant pre-existing immunity exists in humans. Moreover, the vaccine is stable at room temperature for at least one month and is produced at high yields using established commercial manufacturing processes in the gene therapy industry. Thus, this methodology holds as a very promising single dose, thermostable vaccine platform well-suited to address emerging pathogens on a global scale.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.01.05.422952v1" target="_blank">Immunogenicity of an AAV-based, room-temperature stable, single dose COVID-19 vaccine in mice and non-human primates</a>
</div></li>
<li><strong>Crystallographic molecular replacement using an in silico-generated search model of SARS-CoV-2 ORF8</strong> -
<div>
The majority of crystal structures are determined by the method of molecular replacement (MR). The range of application of MR is limited mainly by the need for an accurate search model. In most cases, pre-existing experimentally determined structures are used as search models. In favorable cases, ab initio predicted structures have yielded search models adequate for molecular replacement. The ORF8 protein of SARS-CoV-2 represents a challenging case for MR using an ab initio prediction because ORF8 has an all beta-sheet fold and few orthologs. We previously determined experimentally the structure of ORF8 using the single anomalous dispersion (SAD) phasing method, having been unable to find an MR solution to the crystallographic phase problem. Following a report of an accurate prediction of the ORF8 structure, we assessed whether the predicted model would have succeeded as an MR search model. A phase problem solution was found, and the resulting structure was refined, yielding structural parameters equivalent to the original experimental solution.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.01.05.425441v1" target="_blank">Crystallographic molecular replacement using an in silico-generated search model of SARS-CoV-2 ORF8</a>
</div></li>
<li><strong>SARS-CoV-2 and SARS-CoV spike-mediated cell-cell fusion differ in the requirements for receptor expression and proteolytic activation</strong> -
<div>
The SARS-Coronavirus-2 (SARS-CoV-2) infects cells through interaction of its spike protein (SARS2-S) with the ACE2 receptor and activation by proteases, in particular TMPRSS2. Viruses can also spread through fusion of infected with uninfected cells. We compared the requirements of ACE2 expression, proteolytic activation, and the sensitivity to inhibitors for SARS2-S-mediated and SARS1-S-mediated cell-cell fusion. SARS2-S-driven fusion was moderately increased by TMPRSS2 and strongly by ACE2, while SARS1-S-driven fusion was strongly dependent on activation by TMPRSS2 and less so on ACE2 expression. In contrast to SARS1-S, SARS2-S-mediated cell-cell fusion was efficiently activated by Batimastat-sensitive metalloproteases. Mutation of the S1/S2 proteolytic cleavage site reduced effector-target-cell fusion when ACE2 or TMPRSS2 were limiting and rendered SARS2-S-driven cell-cell fusion more dependent on TMPRSS2. When both ACE2 and TMPRSS2 were abundant, initial target-effector-cell fusion was unaltered compared to wt SARS2-S, but syncytia remained smaller over time. Mutation of the S2' site specifically abrogated activation by TMPRSS2 for both cell-cell fusion and SARS2-S-driven pseudoparticle entry but still allowed for activation by metalloproteases for cell-cell fusion and by cathepsins for particle entry. Finally, we found that the TMPRSS2 inhibitor Bromhexine was unable to reduce TMPRSS2-activated cell-cell fusion by SARS1-S and SARS2-S as opposed to the inhibitor Camostat. Paradoxically, Bromhexine enhanced cell-cell fusion in the presence of TMPRSS2, while its main metabolite Ambroxol exhibited weak inhibitory activity in some conditions. On Calu-3 lung cells, Ambroxol weakly inhibited SARS2-S-driven lentiviral pseudoparticle entry, and both substances exhibited a dose-dependent trend towards weak inhibition of authentic SARS-CoV-2.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2020.07.25.221135v3" target="_blank">SARS-CoV-2 and SARS-CoV spike-mediated cell-cell fusion differ in the requirements for receptor expression and proteolytic activation</a>
</div></li>
<li><strong>SARS-CoV-2 susceptibility of cell lines and substrates commonly used in diagnosis and isolation of influenza and other viruses</strong> -
<div>
Coinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other viruses is inevitable as the COVID-19 pandemic continues. This study aimed to evaluate cell lines commonly used in virus diagnosis and isolation for their susceptibility to SARS-CoV-2. While multiple kidney cell lines from monkeys were susceptible and permissive to SARS-CoV-2, many cell types derived from human, dog, mink, cat, mouse, or chicken were not. Analysis of MDCK cells, which are most commonly used for surveillance and study of influenza viruses, demonstrated that they were insusceptible to SARS-CoV-2 and that the cellular barrier to productive infection was due to low expression level of the angiotensin converting enzyme 2 (ACE2) receptor and lower receptor affinity to SARS-CoV-2 spike, which could be overcome by over-expression of canine ACE2 in trans. Moreover, SARS-CoV-2 cell tropism did not appear to be affected by a D614G mutation in the spike protein.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.01.04.425336v1" target="_blank">SARS-CoV-2 susceptibility of cell lines and substrates commonly used in diagnosis and isolation of influenza and other viruses</a>
</div></li>
<li><strong>Synergistic interferon alpha-based drug combinations inhibit SARS-CoV-2 and other viral infections in vitro</strong> -
<div>
Antiviral drugs are powerful tools to combat emerging viral diseases, one of the leading causes of morbidity and mortality in the world. However, most existing antivirals have failed to cure COVID-19. Accordingly, there is an urgent need for new therapeutics with powerful antiviral and tolerable side effects. Here, we observed that recombinant human interferon-alpha (IFNa) triggered cell intrinsic and extrinsic antiviral responses and reduced replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human lung epithelial Calu-3 cells. However, IFNa alone was insufficient to completely abolish SARS-CoV-2 replication. The combinations of IFNa with camostat, remdesivir, EIDD-2801, cycloheximide or convalescent serum showed strong synergy and, therefore, effectively inhibited SARS-CoV-2 infection. Additionally, we demonstrated synergistic antiviral activity of IFNa2a with pimodivir against influenza A virus (FluAV) infection in human lung epithelial A549 cells, as well as IFNa2a with lamivudine against human immunodeficiency virus 1 (HIV-1) infection in human TZM-bl cells. Our results indicate that IFNa2a-based combinational therapies help to reduce drug dose and improve efficacy in comparison with monotherapies, making them attractive targets for further pre-clinical and clinical development. Additionally, they have powerful treatment potential, and can be leveraged for use in the inhibition of not only emerging or re-emerging viruses, but also immune-evading or drug-resistant viral variants, and viral co-infections.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.01.05.425331v1" target="_blank">Synergistic interferon alpha-based drug combinations inhibit SARS-CoV-2 and other viral infections in vitro</a>
</div></li>
</ul>
<h1 data-aos="fade-right" id="from-clinical-trials">From Clinical Trials</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Dendritic Cell Vaccine to Prevent COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Intervention</b>:   Biological: AV-COVID-19<br/><b>Sponsors</b>:   Indonesia-MoH;   Aivita Biomedical, Inc.;   PT AIVITA Biomedika Indonesia;   National Institute of Health Research and Development, Ministry of Health Republic of Indonesia;   RSUP Dr. Kariadi Semarang, indonesia;   Faculty of Medicine University of Diponegoro, Indonesia<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Inhaled Ivermectin and COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Intervention</b>:   Drug: Ivermectin Powder<br/><b>Sponsor</b>:   Mansoura University<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>AZD1222 Vaccine in Combination With rAd26-S (Component of Gam-COVID-Vac Vaccine) for the Prevention of COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Biological: AZD1222;   Biological: rAd26-S<br/><b>Sponsors</b>:   AstraZeneca;   R-Pharm;   The Russian Direct Investment Fund (RDIF);   The Gamaleya National Center of Epidemiology &amp; Microbiology<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Effect of Deep Breathing Exercise on Dyspnea, Anxiety and Quality of Life in Patients Treated for COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Intervention</b>:   Behavioral: Deep Breathing Exercise with Triflo<br/><b>Sponsor</b>:   Ankara University<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC</strong> - <b>Condition</b>:   COVID-19 Vaccine<br/><b>Interventions</b>:   Biological: ERUCOV-VAC;   Other: Placebo Vaccine<br/><b>Sponsors</b>:   Health Institutes of Turkey;   TC Erciyes University<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Study in Adults to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, Given in Combination With rAd26-S, Recombinant Adenovirus Type 26 Component of Gam-COVID-Vac Vaccine, for the Prevention of COVID-19.</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Biological: AZD1222;   Biological: rAd26-S<br/><b>Sponsors</b>:   R-Pharm;   AstraZeneca<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Biological: AV-COVID-19;   Other: GM-CSF<br/><b>Sponsors</b>:   Aivita Biomedical, Inc.;   PT AIVITA Biomedika Indonesia;   Indonesia Ministry of Health;   National Institute of Health Research and Development, Ministry of Health Republic of Indonesia<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Drug: Anakinra;   Drug: Placebo<br/><b>Sponsor</b>:   Hellenic Institute for the Study of Sepsis<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Evaluating the Impact of EnteraGam In People With COVID-19</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Dietary Supplement: Bovine Plasma-Derived Immunoglobulin Concentrate;   Other: Standard of care<br/><b>Sponsors</b>:   Entera Health, Inc;   Lemus Buhils, SL;   Clinical Research Unit, IMIM (Hospital del Mar Medical Research Institute)<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult</strong> - <b>Condition</b>:   Covid19 Vaccine<br/><b>Interventions</b>:   Biological: MVC-COV1901(S protein with adjuvant);   Biological: MVC-COV1901(Saline)<br/><b>Sponsor</b>:   Medigen Vaccine Biologics Corp.<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Surgical Face Mask Effects in Patients With COVID-19</strong> - <b>Condition</b>:   Covid19<br/><b>Intervention</b>:   Other: Sit-To-Stand test<br/><b>Sponsor</b>:   Cliniques universitaires Saint-Luc- Université Catholique de Louvain<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Efficacy of Favipiravir in Treatment of Mild &amp; Moderate COVID-19 Infection in Nepal</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Drug: Favipiravir;   Drug: Placebo;   Drug: Remdesivir<br/><b>Sponsor</b>:   Nepal Health Research Council<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Biological: SCTA01;   Biological: SCTA01 Placebo<br/><b>Sponsor</b>:   Sinocelltech Ltd.<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home</strong> - <b>Condition</b>:   Covid19<br/><b>Intervention</b>:   Drug: tenofovir disoproxil and emtricitabine<br/><b>Sponsor</b>:   University Hospital, Caen<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>RescuE pLAsma eXchange in Severe COVID-19</strong> - <b>Conditions</b>:   Therapeutic Plasma Exchange;   Covid19<br/><b>Intervention</b>:   Other: Therapeutic plasma exchange<br/><b>Sponsor</b>:   Heidelberg University<br/><b>Not yet recruiting</b></p></li>
</ul>
<h1 data-aos="fade-right" id="from-pubmed">From PubMed</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Compassionate use of Ruxolitinib in patients with SarsCov-2 infection not on mechanical ventilation. Short-term effects on inflammation and ventilation</strong> - Ruxolitinib is an anti-inflammatory drug that inhibits the Janus kinase-signal transducer (JAK-STAT) pathway on the surface of immune cells. The potential targeting of this pathway using JAK inhibitors is a promising approach in patients affected by COVID-19 disease. Ruxolitinib was provided as a compassionate use in patients consecutively admitted to our institution for Sars-CoV-2 infection. Inclusion criteria were oxygen saturation ≤ 92%, signs of interstitial pneumoniae, and no need of...</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Beneficial Effects of Intermediate Dosage of Anticoagulation Treatment on the Prognosis of Hospitalized COVID-19 Patients: The ETHRA Study</strong> - CONCLUSION: Anticoagulation treatment (particularly intermediate dosage) appears to have positive impact on COVID-19 inpatients' prognosis by inhibiting both coagulation and inflammatory cascades.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Computational analysis of dynamic allostery and control in the SARS-CoV-2 main protease</strong> - The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 has no publicly available vaccine or antiviral drugs at the time of writing. An attractive coronavirus drug target is the main protease (M^(pro), also known as 3CL^(pro)) because of its vital role in the viral cycle. A significant body of work has been focused on finding inhibitors which bind and block the active site of the main protease, but little has been done to address potential non-competitive inhibition, targeting regions...</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Surface interactions and viability of coronaviruses</strong> - The recently emerged coronavirus pandemic (COVID-19) has become a worldwide threat affecting millions of people, causing respiratory system related problems that can end up with extremely serious consequences. As the infection rate rises significantly and this is followed by a dramatic increase in mortality, the whole world is struggling to accommodate change and is trying to adapt to new conditions. While a significant amount of effort is focused on developing a vaccine in order to make a...</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Using in silico modelling and FRET-based assays in the discovery of novel FDA-approved drugs as inhibitors of MERS-CoV helicase</strong> - A Förster resonance energy transfer (FRET)-based assay was used to screen the FDA-approved compound library against the MERS-CoV helicase, an essential enzyme for virus replication within the host cell. Five compounds inhibited the helicase activity with submicromolar potencies (IC(50), 0.73-1.65 µM) and ten compounds inhibited the enzyme with micromolar potencies (IC(50), 19.6-502 µM). The molecular operating environment (MOE) was used to dock the identified inhibitors on the MERS-CoV helicase...</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 and the revival of passive immunization: Antibody therapy for inhibiting SARS-CoV-2 and preventing host cell infection: IUPHAR review: 31</strong> - The COVID-19 pandemic urged both scientific community and health care companies to undertake an unprecedented effort with the aim of understanding the molecular mechanisms of SARS-CoV-2 infection and developing effective therapeutic solutions. The peculiar immune response triggered by such virus, that seems to last only few months, induced to look for alternatives such as passive immunization in addition to conventional vaccinations. Convalescent sera, monoclonal antibodies selected among the...</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>In vitro Targeting of Transcription Factors to Control the Cytokine Release Syndrome in COVID-19</strong> - Treatment of the cytokine release syndrome (CRS) has become an important part of rescuing hospitalized COVID-19 patients. Here, we systematically explored the transcriptional regulators of inflammatory cytokines involved in the COVID-19 CRS to identify candidate transcription factors (TFs) for therapeutic targeting using approved drugs. We integrated a resource of TF-cytokine gene interactions with single-cell RNA-seq expression data from bronchoalveolar lavage fluid cells of COVID-19 patients....</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Structural basis for broad coronavirus neutralization</strong> - Three highly pathogenic β-coronaviruses crossed the animal-to-human species barrier in the past two decades: SARS-CoV, MERS-CoV and SARS-CoV-2. SARS-CoV-2 has infected more than 64 million people worldwide, claimed over 1.4 million lives and is responsible for the ongoing COVID-19 pandemic. We isolated a monoclonal antibody, termed B6, cross-reacting with eight β-coronavirus spike glycoproteins, including all five human-infecting β-coronaviruses, and broadly inhibiting entry of pseudotyped...</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Potent in vitro anti-SARS-CoV-2 activity by gallinamide A and analogues via inhibition of cathepsin L</strong> - The emergence of SARS-CoV-2 in late 2019, and the subsequent COVID-19 pandemic, has led to substantial mortality, together with mass global disruption. There is an urgent need for novel antiviral drugs for therapeutic or prophylactic application. Cathepsin L is a key host cysteine protease utilized by coronaviruses for cell entry and is recognized as a promising drug target. The marine natural product, gallinamide A and several synthetic analogues, were identified as potent inhibitors of...</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19: inflammatory responses, structure-based drug design and potential therapeutics</strong> - The COVID-19 pandemic caused by SARS-CoV-2 is responsible for the global health emergency. Here, we explore the diverse mechanisms of SARS-CoV-induced inflammation. We presume that SARS-CoV-2 likely contributes analogous inflammatory responses. Possible therapeutic mechanisms for reducing SARS-CoV-2-mediated inflammatory responses comprise FcR inactivation. Currently, there is no specific remedy available against the SARS-CoV-2. Consequently, recognizing efficacious antiviral leads to combat the...</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Structural characteristics and catalytic cycle of dihydroorotate dehydrogenase-a review</strong> - Dihydroorotate dehydrogenase is a flavin-dependent mitochondrial enzyme to catalyze the fourth step of the de novo synthesis of pyrimidine and to oxidize dihydroorotate to orotate. By selectively inhibiting dihydroorotate dehydrogenase, thereby inhibiting pyrimidine synthesis, the enzyme has been developed for the treatment of cancer, autoimmune diseases, bacterial or viral infections, parasitic diseases and so on. The development of inhibitory drugs requires a detailed understanding of the...</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Changes in inflammatory and immune drivers in response to immunomodulatory therapies in COVID-19</strong> - As the global community strives to discover effective therapies for COVID-19, immunomodulatory strategies have emerged as a leading contender to combat the cytokine storm and improve clinical outcomes in patients with severe disease. Systemic corticosteroids and selective cytokine inhibitory agents have been utilized both as empiric therapies and in clinical trials. While multiple randomized, placebo controlled trials have now demonstrated that corticosteroids improve survival in patients with...</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Potential therapeutic approaches of microRNAs for COVID-19: Challenges and opportunities</strong> - The coronavirus disease 2019 (COVID-19) emerges as current outbreak cause by Novel Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2). This infection affects respiratory system and provides uncontrolled systemic inflammatory response as cytokine storm. The main concern about SARS-CoV-2 pandemic is high viral pathogenicity with no specific drugs. MicroRNAs (miRs) as small non-coding RNAs (21-25 nt) regulate gene expression. The SARS-CoV-2 encoded-miRs affect human genes that involved...</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Southeast Asian Perspective on the COVID-19 Pandemic: Hemoglobin E (HbE)-Trait Confers Resistance Against COVID-19</strong> - As of November 25, 2020, over 60 million people have been infected worldwide by COVID-19, causing almost 1.43 million deaths. Puzzling low incidence numbers and milder, non-fatal disease have been observed in Thailand and its Southeast (SE) Asian neighbors. Elusive genetic mechanisms might be operative, as a multitude of genetic factors are widely shared between the SE Asian populations, such as the more than 60 different thalassemia syndromes (principally dominated by the HbE trait). In this...</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Stereotypic neutralizing V(H) antibodies against SARS-CoV-2 spike protein receptor binding domain in COVID-19 patients and healthy individuals</strong> - Stereotypic antibody clonotypes exist in healthy individuals and may provide protective immunity against viral infections by neutralization. We observed that 13 out of 17 patients with COVID-19 had stereotypic variable heavy chain (V(H)) antibody clonotypes directed against the receptor-binding domain (RBD) of SARS-CoV-2 spike protein. These antibody clonotypes were comprised of immunoglobulin heavy variable (IGHV)3-53 or IGHV3-66 and immunoglobulin heavy joining (IGHJ)6 genes. These clonotypes...</p></li>
</ul>
<h1 data-aos="fade-right" id="from-patent-search">From Patent Search</h1>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Covid 19 - Chewing Gum</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU313269181">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A traditional Chinese medicine composition for COVID-19 and/or influenza and preparation method thereof</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU313300659">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>STOCHASTIC MODEL METHOD TO DETERMINE THE PROBABILITY OF TRANSMISSION OF NOVEL COVID-19</strong> - The present invention is directed to a stochastic model method to assess the risk of spreading the disease and determine the probability of transmission of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN313339294">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The use of human serum albumin (HSA) and Cannabigerol (CBG) as active ingredients in a composition for use in the treatment of Coronavirus (Covid-19) and its symptoms</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU313251184">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The use of human serum albumin (HSA) and Cannabigerol (CBG) as active ingredients in a composition for use in the treatment of Coronavirus (Covid-19) and its symptoms</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU313251182">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>抑制病毒受体ACE2的COVID-19防治药物及其应用</strong> - 本发明提供了一种抑制病毒受体ACE2的COVID‑19防治药物及其应用。具体地说，本发明提供了中药鹅不食草在制备调节ACE2表达量的药物中的应用。本发明还提供了中药鹅不食草单独或与其它药物组合在制备COVID‑19防治药物中的应用。本发明发现鹅不食草能够使正常肺上皮细胞中ACE2的表达降低，从而降低新型冠状病毒(SARS‑CoV‑2)感染的风险，发挥预防SARS‑CoV‑2感染及治疗COVID‑19的作用。中药鹅不食草成本低，毒副作用小，疗效显著，为COVID‑19的治疗提供了新策略。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN313773195">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>"AYURVEDIC PROPRIETARY MEDICINE FOR TREATMENT OF SEVERWE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2."</strong> - AbstractAyurvedic Proprietary Medicine for treatment of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)In one of the aspect of the present invention it is provided that Polyherbal combinations called Coufex (syrup) is prepared as Ayurvedic Proprietary Medicine , Aqueous Extracts Mixing with Sugar Syrup form the following herbal aqueous extract coriandrum sativum was used for the formulation of protek.Further another Polyherbal combination protek as syrup is prepared by the combining an aqueous extract of the medicinal herbs including Emblica officinalis, Terminalia chebula, Terminalia belerica, Aegle marmelos, Zingiber officinale, Ocimum sanctum, Adatoda zeylanica, Piper lingum, Andrographis panivulata, Coriandrum sativum, Tinospora cordiofolia, cuminum cyminum,piper nigrum was used for the formulation of Coufex. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN312324209">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물</strong> - 본 발명은 화학식 1로 표시되는 화합물, 또는 이의 약학적으로 허용가능한 염; 및 글루카곤 수용체 작용제(glucagon receptor agonist), 위 억제 펩타이드(gastric inhibitory peptide, GIP), 글루카곤-유사 펩타이드 1(glucagon-like peptide 1, GLP-1) 및 글루카곤 수용체/위 억제 펩타이드/글루카곤-유사 펩타이드 1(Glucagon/GIP/GLP-1) 삼중 완전 작용제(glucagon receptors, gastric inhibitory peptide and glucagon-like peptide 1 (Glucagon/GIP/GLP-1) triple full agonist)로 이루어진 군으로부터 선택된 1종 이상;을 포함하는 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환 예방 또는 치료용 약학적 조성물을 제공한다. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=KR313434044">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Haptens, hapten conjugates, compositions thereof and method for their preparation and use</strong> - A method for performing a multiplexed diagnostic assay, such as for two or more different targets in a sample, is described. One embodiment comprised contacting the sample with two or more specific binding moieties that bind specifically to two or more different targets. The two or more specific binding moieties are conjugated to different haptens, and at least one of the haptens is an oxazole, a pyrazole, a thiazole, a nitroaryl compound other than dinitrophenyl, a benzofurazan, a triterpene, a urea, a thiourea, a rotenoid, a coumarin, a cyclolignan, a heterobiaryl, an azo aryl, or a benzodiazepine. The sample is contacted with two or more different anti-hapten antibodies that can be detected separately. The two or more different anti-hapten antibodies may be conjugated to different detectable labels. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU311608060">link</a></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Mundschutz für Brillenträger und Brillenadapter</strong> -
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
</p><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Mundschutz bestehend aus einem Abdeckteil für den Mund- und gegebenenfalls den Nasenbereich des Gesichts und einem Bandteil mit mindestens einem Halteband, welches mit den Seiten des Abdeckteil verbunden ist und zur Befestigung des Mundschutzes dient, wobei das Halteband am seitlichen Ende des Abdeckteils fixiert ist und eine Schlaufe bildet, dadurch gekennzeichnet, dass an der Schlaufe des Haltebands ein Clip befestigt ist.</p></li>
</ul>
<img alt="embedded image" id="EMI-D00000"/>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
<ul>
<li><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=DE313866570">link</a></li>
</ul>
<script>AOS.init();</script></body></html>

601
archive-daily-dose/06 January, 2021.html Normal file
View File

@ -0,0 +1,601 @@
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"><head>
<meta content="text/html; charset=utf-8" http-equiv="Content-Type"/>
<meta content="text/css" http-equiv="Content-Style-Type"/>
<meta content="pandoc" name="generator"/>
<title></title>
<style type="text/css">code{white-space: pre;}</style>
<title>Daily-Dose</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><style>*{overflow-x:hidden;}</style><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
<body>
<h1 data-aos="fade-down" id="daily-dose">Daily-Dose</h1>
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
<ul>
<li><a href="#from-new-yorker">From New Yorker</a></li>
<li><a href="#from-vox">From Vox</a></li>
<li><a href="#from-the-hindu-sports">From The Hindu: Sports</a></li>
<li><a href="#from-the-hindu-national-news">From The Hindu: National News</a></li>
<li><a href="#from-bbc-europe">From BBC: Europe</a></li>
<li><a href="#from-ars-technica">From Ars Technica</a></li>
<li><a href="#from-jokes-subreddit">From Jokes Subreddit</a></li>
</ul>
<h1 data-aos="fade-right" id="from-new-yorker">From New Yorker</h1>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Trump’s Authoritarian Moment Is Here</strong> - Far too many Republicans are complicit in the President’s continuing efforts to overturn the election results. - <a href="https://www.newyorker.com/news/our-columnists/trumps-authoritarian-moment-is-here">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>What the San Francisco Bay Area Can Teach Us About Fighting a Pandemic</strong> - The region’s hyper-local response has lessons for us as we confront the winter wave and begin to distribute vaccines. - <a href="https://www.newyorker.com/news/california-chronicles/what-the-san-francisco-bay-area-can-teach-us-about-fighting-a-pandemic">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Georgia’s Senate Runoff Elections: Live Updates</strong> - The latest results in the races that will decide control of the U.S. Senate. - <a href="https://www.newyorker.com/news/election-2020/georgias-senate-runoff-elections-live-updates">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Donald Trump’s Alarming Call to Battle in Georgia</strong> - The outgoing President is fighting not for his legacy but to unconstitutionally and criminally hold on to a position that he has already lost. - <a href="https://www.newyorker.com/news/daily-comment/trumps-alarming-call-to-battle-in-georgia">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Test for Congress’s Commitment to Democracy</strong> - Lawmakers who do not support Donald Trump’s effort to subvert the election will need to keep their wits about them. - <a href="https://www.newyorker.com/news/our-columnists/trump-and-republicans-in-congress-could-still-jeopardize-the-election">link</a></p></li>
</ul>
<h1 data-aos="fade-right" id="from-vox">From Vox</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>5 winners and 2 losers from the Georgia Senate elections</strong> -
<figure>
<img alt="" src="https://cdn.vox-cdn.com/thumbor/72geXkwvXOFkbCEihYOzaKI8t28=/257x0:2924x2000/1310x983/cdn.vox-cdn.com/uploads/chorus_image/image/68626395/AP_21004800208949.0.jpg"/>
<figcaption>
Democrats Rev. Raphael Warnock and Jon Ossoff have delivered Senate majority to President-Elect Joe Biden. | Carolyn Kaster/AP
</figcaption>
</figure></li>
</ul>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Democrats’ double victory will fundamentally change the next two years of American politics.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="qyEQ3V">
It’s finally over: Five full days after the actual year 2020 ended, the 2020 elections have ended too.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Inrdmz">
And they ended with a bang early Wednesday morning, a slim but decisive victory by Democrats Raphael Warnock and Jon Ossoff, who in one fell swoop turned both of Georgia’s US Senate seats Democratic. In doing so, they ensured that the party will have a razor-thin 50-50 Senate majority once Vice President Kamala Harris takes office on January 20.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="p93AKW">
The results will thus fundamentally change the next two years of American politics. Instead of being hamstrung by an intransigent Republican majority leader in the Senate, President-elect Joe Biden will have a narrow majority in both Houses of Congress. So long as Senate Democrats are in unanimous agreement, Biden will be able to use budget reconciliation to pass further Covid-19 vaccination measures, additional economic stimulus and aid to states and cities, and investments in green energy and caregiving as part of <a href="https://www.vox.com/policy-and-politics/21340746/joe-biden-covid-19-coronavirus-recession-harris">his “Build Back Better” agenda</a>. Policy ideas once considered dead on arrival, like a national public option for health insurance, suddenly look, if not likely, at least<strong> </strong>possible.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="qvfS8u">
That’s only the beginning of the implications of the results from the Georgia special election. Here’s who ended up ahead and who fell behind.
</p>
<h3 id="WFr2t7">
Winners: Raphael Warnock and Jon Ossoff
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="v3pZIR">
This wasn’t supposed to happen.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="TFl02v">
For one thing, there was only supposed to be <em>one</em> Senate election in Georgia this year; the other wasn’t up for reelection until 2022. But Republican Sen. Johnny Isakson surprised everyone in August 2019 by <a href="https://www.vox.com/2019/8/28/20836716/johnny-isakson-georgia-retirement-2020-david-perdue-democratic-senate-majority">announcing his resignation for health reasons</a>, effective at the end of the year. At the time, my colleague Li Zhou <a href="https://www.vox.com/2019/8/28/20836716/johnny-isakson-georgia-retirement-2020-david-perdue-democratic-senate-majority">wrote</a> that the move “could have major implications for Democratic efforts to retake the upper chamber.” Did it ever.
</p>
<figure class="e-image">
<pre><code> &lt;img alt="People at an election rally hold signs, one of which reads, “Ossoff and Warnock,” and one reads, “Vote! Flip the Senate, vote Jan 5.”" src="https://cdn.vox-cdn.com/thumbor/fe2Hp16rTs0vrhl5-hBfid0tQpk=/800x0/filters:no_upscale()/cdn.vox-cdn.com/uploads/chorus_asset/file/22216746/GettyImages_1230426368.jpg" /&gt;
&lt;cite&gt;Jim Watson/AFP via Getty Images&lt;/cite&gt;
&lt;figcaption&gt;Supporters of Democratic candidates for Senate Jon Ossoff and Rev. Raphael Warnock listen to US President-elect Joe Biden speak during a rally in Atlanta, Georgia, on January 4.&lt;/figcaption&gt;</code></pre>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Ml48aF">
But more broadly, Georgia was not supposed to be the tipping point state. In other closely fought states, Democrats really did get their dream candidates. Gov. Steve Bullock ran in Montana; their top recruits in Arizona and Colorado, astronaut Mark Kelly and former Gov. John Hickenlooper, respectively, ran too. Kelly and Hickenlooper won (and Bullock ran ahead of Biden in a deep red state), but in states like North Carolina and Texas where top Democratic prospects didn’t run, the party fell short.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="hxnuZM">
None of the top Georgia Democrats ran in 2020. No incumbent member of the US House stepped up; former gubernatorial nominee <a href="https://www.vox.com/policy-and-politics/2019/4/30/18300345/stacey-abrams-president-2020">Stacey Abrams</a>, national Democrats’ top prospect, declined, as did 2014 governor nominee <a href="https://www.washingtonexaminer.com/news/jimmy-carter-grandson-declines-georgia-senate-bid">Jason Carter</a>, 2014 Senate nominee <a href="https://www.ajc.com/blog/politics/georgia-senate-michelle-nunn-passes-2020-bid/LzvT26oDs4K1C83zIeUIoJ/">Michelle Nunn</a>, and former deputy US Attorney General/Georgia US Attorney <a href="https://www.ajc.com/blog/politics/yates-passes-run-for-georgia-office/eDGLiWT61rPjIkFqGDmNAI/">Sally Yates</a>.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="kRVyo5">
Instead, Warnock and Ossoff, two candidates with no experience in elected office, got the nods. Ossoff in particular, who fell short in a closely watched, heavily funded congressional special election in 2017, felt almost like a default candidate. Warnock has a long background as a pastor that gave him a built-in base; Ossoff had little more than name recognition.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="lWJ0iC">
Both were true underdog candidates. Yes, they got massive national support, in financing and campaigning, especially when it became clear their runoffs would decide control of the US Senate. But they are both unlikely senators, with Ossoff, only 33, becoming arguably the first millennial to join the body. Warnock will be the first Black senator from Georgia, and only the second Black senator from the South since Reconstruction.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="xMvylv">
It’s a huge personal victory for Warnock and Ossoff, even if the national implications of their wins might overshadow that.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="dvm9qR">
—<em>Dylan Matthews</em>
</p>
<h3 id="Lx7Zpc">
Loser: Mitch McConnell
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="1re7Tx">
Shortly after being sworn in to the Senate for his first term in 1985, Mitch McConnell <a href="https://www.vox.com/policy-and-politics/2017/7/17/15970034/mitch-mcconnell-senate-health-bill">set a goal</a> for himself: to become the chamber’s majority leader. It took 30 years, but he finally achieved it in 2014 when, after eight years leading Republicans in the minority, the GOP retook control of the chamber. McConnell then protected his majority through tough election cycles in 2016 and 2018, got three conservative Supreme Court justices confirmed, and won his own reelection for his seventh (and, many believe, final) term in November.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="8yHS1U">
But Republicans’ double defeat in Georgia means McConnell will begin that term as minority, rather than majority, leader — an outcome he has been trying desperately to avoid since it became clear that President Trump lost reelection and that Senate control would be decided in Georgia.
</p>
<figure class="e-image">
<pre><code> &lt;img alt=" " src="https://cdn.vox-cdn.com/thumbor/IJi5fAzROPSNn0Nu6T3-M6oTCoM=/800x0/filters:no_upscale()/cdn.vox-cdn.com/uploads/chorus_asset/file/22216662/GettyImages_1230235843.jpg" /&gt;
&lt;cite&gt;Samuel Corum/Getty Images&lt;/cite&gt;
&lt;figcaption&gt;Sen. Mitch McConnell will now be the Senate minority, rather than majority, leader.&lt;/figcaption&gt;</code></pre>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="ANcuYJ">
His strategy, at first, was to let Trump have some room as the president refused to concede, to avoid dividing the GOP before the runoffs. In his <a href="https://www.vox.com/2020/11/10/21557852/bill-barr-election-memo-mitch-mcconnell-speech-fraud">first Senate floor speech</a> after the election was called for Biden, McConnell snarked about Democratic hypocrisy, said the president was merely pursuing legal options as candidates often do, and <a href="https://www.vox.com/2020/11/10/21557852/bill-barr-election-memo-mitch-mcconnell-speech-fraud">claimed</a> “our system” would work things out. (That’s the day an anonymous senior Republican official <a href="https://www.washingtonpost.com/politics/trump-republicans-election-challenges/2020/11/09/49e2c238-22c4-11eb-952e-0c475972cfc0_story.html">told the Washington Post</a>, “What is the downside for humoring him [Trump] for this little bit of time? No one seriously thinks the results will change.”)
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="QjocZ7">
But if you give Trump an inch, he’ll take a mile, and the president’s frenzied and corrupt (and scattershot and incompetent) effort to dispute the results has not yet ended. He became obsessed with overturning the results in Georgia specifically, pursuing personal feuds against state officials who would not rig the results in his favor. All this culminated <a href="https://www.vox.com/2021/1/4/22211984/trump-raffensperger-georgia-hawley-cruz-election">this past weekend</a> when Trump called Georgia Secretary of State Brad Raffensperger and asked him to “find” votes for him — resulting in Raffensperger’s team leaking a recording of that call, foregrounding Republican disarray two days before the special Senate elections.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="bI6Inz">
To McConnell’s (very limited) credit, he did nothing to outright help Trump’s election-stealing effort (and if you read between the lines of his statements, you <a href="https://twitter.com/awprokop/status/1346132695001260032">could tell</a> he wasn’t on board). Indeed, shortly after the Electoral College voted in mid-December, McConnell did <a href="https://www.vox.com/2020/12/15/22176253/joe-biden-senate-republicans-victory-presidential-election-mitch-mcconnell-trump-results">acknowledge Biden’s win</a>. But in November, he had made the choice to let Trump run wild rather than try to rein him in — and given his stature in Republican politics, that was a signal to many other GOP politicians that they should do the same.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="dDE9yD">
It’s far from clear whether, if McConnell had more forthrightly challenged Trump back in November, it would have changed Tuesday’s outcomes. (It may well have made things worse if Trump had declared war on the Senate GOP rather than campaigning for Loeffler and Warnock.) But in addition to the Trump fallout, another recent McConnell decision — his refusal to allow the Senate to vote on a clean measure to send out $2,000 stimulus checks — will also be in for some second-guessing. What’s clear is that the post-election period has been a disaster for McConnell, and that his long-cherished prize has slipped out of his fingers — at least for now.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="SBPfii">
—<em>Andrew Prokop</em>
</p>
<h3 id="z4r0Gh">
Loser: Trump’s election discrediting strategy
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="pac0PP">
It’s still too early to say exactly why the Republicans blew what seemed like two winnable Senate races. But there’s good reason to believe that President Trump — and his anti-democratic attempts to overturn the presidential election in Georgia and other states — will end up shouldering a significant portion of the blame.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="MlZzrz">
There are at least two reasons to believe that Trump’s attacks on the election hurt Loeffler and Perdue.
</p>
<figure class="e-image">
<pre><code> &lt;img alt=" " src="https://cdn.vox-cdn.com/thumbor/8_2ssC8W-WnnjCBurpqJKXvn0pE=/800x0/filters:no_upscale()/cdn.vox-cdn.com/uploads/chorus_asset/file/22216673/GettyImages_1230429308.jpg" /&gt;
&lt;cite&gt;Sandy Huffaker/AFP via Getty Images&lt;/cite&gt;
&lt;figcaption&gt;President Trump campaigns alongside Sen. Kelly Loeffler in Dalton, Georgia, on January 4.&lt;/figcaption&gt;</code></pre>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="FHriRM">
First, his repeated attack on the integrity of the electoral process — arguing that Georgia, in particular, experienced massive fraud in the presidential election — seems to have convinced many Republicans that the election was in fact fraudulent. CNN’s exit polls <a href="https://www.forbes.com/sites/andrewsolender/2021/01/05/georgia-exit-polls-reveal-staggering-partisan-divide-in-election-confidence/?sh=326f7e7f6306">found that 76 percent of Republican voters</a> believed the state’s presidential election wasn’t fair, and Republican turnout was <a href="https://twitter.com/Redistrict/status/1346628431019200513">on the lower end</a> compared to expectations. While exit polls aren’t super reliable, it’s possible that a small but crucial number of Republicans were so committed to Trump’s fraud claims that they didn’t even bother to show up at the polls — a boycott encouraged by some Trump allies angry at the national party for not going all-in on his claims.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="YFxgMb">
Second, Trump’s attack on the election inflamed Democrats and helped nationalize the races in a particularly unhelpful way, turning what could have been contests driven by local considerations into a referendum on Trump in a state he lost. It’s possible that Republican attacks on Ossoff and Warnock might have been more effective if Trump weren’t constantly in the news; it’s also possible that Loeffler and Perdue might have benefited more from <a href="http://eastcobbnews.com/mcbath-loeffler-and-perdue-vote-for-covid-relief-package/">their votes in favor</a> of the <a href="https://fivethirtyeight.com/features/both-republicans-and-democrats-want-congress-to-approve-a-new-coronavirus-stimulus-package/">popular coronavirus relief bill</a> if Trump’s election shenanigans weren’t front and center.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="2WNseO">
To be clear: It’s way too early to say with certainty what role, if any, Trump played in Georgia’s results. But these theories are likely to become a staple of cable news insta-postmortems and the GOP circular firing squad that will emerge on Wednesday morning. The more this becomes part of the public narrative of what happened in Georgia, the worse Trump’s election attacks will look even among partisan Republicans.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="ViWjcv">
That’s a good thing for American democracy.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="TdXrC7">
<em>—Zack Beauchamp</em>
</p>
<h3 id="pvakoE">
Winner: Joe Manchin
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="W7Lbgh">
In just over two weeks, Joe Biden becomes the president of the United States. Warnock’s and Ossoff’s victories mean that Republicans in the House and Senate will not be able to actively sabotage the executive branch of the federal government. With a Democratic Senate, Biden will be able to confirm a Cabinet, confirm at least some judges, and sign at least some spending bills thanks to a process known as “<a href="https://www.vox.com/policy-and-politics/2016/11/23/13709518/budget-reconciliation-explained">budget reconciliation</a>.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="DMIs2s">
But the balance of power in that Senate will be held by Sen. Joe Manchin (D-WV), the most conservative member of the Democratic caucus. If Republicans unite in opposition to a Biden nominee, it will most likely be Manchin who decides whether that individual is confirmed. When Biden hopes to negotiate a budget or a new Covid-19 relief bill, Manchin will play an outsize role in those negotiations.
</p>
<figure class="e-image">
<pre><code> &lt;img alt=" " src="https://cdn.vox-cdn.com/thumbor/gHmNfGunvIPYjVSM1QTEY_J7qhU=/800x0/filters:no_upscale()/cdn.vox-cdn.com/uploads/chorus_asset/file/22216688/GettyImages_1230129930.jpg" /&gt;
&lt;cite&gt;Caroline Brehman/CQ-Roll Call via Getty Images&lt;/cite&gt;
&lt;figcaption&gt;Sen. Joe Manchin (D-WV) unveils a proposal for a Covid-19 relief bill alongside a group of bipartisan lawmakers on December 14, 2020.&lt;/figcaption&gt;</code></pre>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="ML4ol1">
Biden will control the executive branch, but it is only somewhat of an exaggeration to say that Joe Manchin — the most likely tipping point for any number of measures —<strong> </strong>will control the legislative branch. Manchin, it’s worth noting, has a <a href="https://www.usatoday.com/story/news/politics/2020/12/21/how-covid-19-relief-deal-came-together-over-pasta-dinner-zoom-chats/3974081001/">record of working with Republican senators</a> like Susan Collins (ME), Lisa Murkowski (AK), and Mitt Romney (UT), all of whom occasionally break from their party on significant votes. But where he disagrees with his sometime Republican allies, Manchin is likely to hold the 50th vote in the Senate, and the power to decide whether important matters succeed or fail.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="ku6wGH">
Whenever a controversy arises in Congress, the first question on every reporter’s lips will be “what does Sen. Manchin think?” Not long after it became clear that Warnock and Ossoff were likely to prevail, <a href="https://twitter.com/CitizenCohn/status/1346647392632893443">Joe Manchin’s name started trending on Twitter</a>.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="A6Airz">
Unfortunately for Biden — <a href="https://www.vox.com/21424582/filibuster-joe-biden-2020-senate-democrats-abolish-trump">and for America</a> — Manchin also gains the power to decide whether most of Biden’s legislative agenda will be dead on arrival. Manchin is a <a href="https://www.nytimes.com/2020/11/30/us/politics/joe-manchin-interview.html">staunch opponent of abolishing the filibuster</a>, the antiquated process that allows a minority of the Senate to block most legislation unless 60 senators agree to end that blockade.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="vh8dV1">
Republicans will no doubt deploy the filibuster ruthlessly against Biden, just as they <a href="https://www.vox.com/2015/2/9/8006121/obama-filibuster-elimination">deployed it against President Obama</a>. Meanwhile, Democrats and liberal policy wonks are likely to come up with various plans to weaken the filibuster without abolishing it — I’ve proposed <a href="https://www.vox.com/2020/6/22/21293168/dc-statehood-vote-filibuster-supreme-court-joe-biden">exempting statehood bills from the filibuster</a>, for example.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="UEj8eQ">
Will any of these proposals to weaken but not eliminate the filibuster prevail? That’s likely up to Joe Manchin.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="LC7aPG">
—<em>Ian Millhiser</em>
</p>
<h3 id="OhwmqW">
Winner: Stacey Abrams and Georgia organizers
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="GOTz9T">
The real face of Democrats’ victory in Georgia isn’t Jon Ossoff or Raphael Warnock; it’s Stacey Abrams.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="AWn5U3">
Abrams, the 2018 Democratic gubernatorial candidate and founder of the voting rights group Fair Fight, was encouraged by many to run for the Senate herself. Instead, she opted to help organize, along with dozens of other voting rights groups.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="R7ogv1">
She had long argued that Georgia was on the cusp of becoming a swing state and could get there given enough<strong> </strong>dedicated resources and organizing. Years of hard work from dozens of groups <a href="https://www.vox.com/21755028/democrats-ossoff-warnock-georgia-runoffs-explained">made it a reality</a>; first with Biden’s November win, and then with Ossoff’s and Warnock’s stunning January victories.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="3vbeI1">
“Our time is now,” Abrams told Vox in an email interview shortly before the November election.
</p>
<figure class="e-image">
<pre><code> &lt;img alt="Two women in pink breathing masks hold up “vote signs, one with a drawing of Jon Ossoff and one with a drawing of Stacey Abrams." src="https://cdn.vox-cdn.com/thumbor/iAT6eI-Z-ueMYgRz4gdMX-9SI2U=/800x0/filters:no_upscale()/cdn.vox-cdn.com/uploads/chorus_asset/file/22216699/GettyImages_1230426491.jpg" /&gt;
&lt;cite&gt;Jim Watson/AFP via Getty Images&lt;/cite&gt;
&lt;figcaption&gt;Stacey Abrams and local organizers have successfully made Georgia a swing state.&lt;/figcaption&gt;</code></pre>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="XG8LcK">
Between the 2018 midterms where Abrams narrowly lost the governor’s race and the November 2020 election, 800,000 Georgians registered to vote. And there was no rest for Georgia’s voting organizers from November to January.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="2NH9oJ">
“We do voter registration 365 days a year, not just during a major election,” Deborah Scott, the executive director of Georgia Stand-Up, told Vox recently.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="YCoFoH">
A coalition of dozens of groups coordinated by America Votes knocked on 8.5 million doors in Georgia; they also made about 20 million phone calls and sent over 18 million texts. Some groups got creative in the pursuit of turning out low-propensity voters, mobilizing with food drives and Thanksgiving turkey giveaways to encourage people to register and get out to the polls.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="9bbfZo">
Ultimately, their work paid off in a huge way, proving that Joe Biden’s November win in Georgia wasn’t an aberration.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="S3PApC">
“Folks didn’t allow themselves to hope,” said Nsé Ufot, CEO of the voting rights group New Georgia Project. “Ultimately, you have to conceive of it first before we can build it; folks have to believe that it’s possible.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="TGkYY9">
—<em>Ella Nilsen</em>
</p>
<h3 id="dxPci2">
Winner: Ketanji Brown Jackson (or Leondra Kruger)
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="NOSv40">
The last time a Democrat was president and Republicans controlled the Senate, in 2015 and 2016, Mitch McConnell <a href="https://www.vox.com/policy-and-politics/2019/12/9/20962980/trump-supreme-court-federal-judges">nearly shut down all confirmations to the federal appellate bench</a>. And, of course, there was that whole affair with Judge Merrick Garland, the Obama Supreme Court nominee who wasn’t even given a confirmation hearing by a Republican Senate.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="jFxhuD">
Had Republicans maintained control of the Senate, it’s likely that McConnell would have repeated this performance. Biden could have struggled to confirm <em>any</em> judge, much less a nominee to a powerful appeals court. And a Biden Supreme Court nominee could very well have not even been considered.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="3VjjUR">
But with Democrats controlling the Senate, even by a narrow margin, McConnell will not be able to blockade the judiciary. Among other things, that means that Justice Stephen Breyer, the 82-year-old Clinton appointee to the Supreme Court, can retire knowing that his replacement-in-waiting will not suffer Garland’s fate.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="CI7uyN">
Biden, meanwhile, has <a href="https://www.vox.com/2020/2/25/21153824/biden-black-woman-supreme-court">promised to name a Black woman</a> to the Supreme Court. If a vacancy arises on the high Court after Biden has already named many judges to the lower courts, Biden will likely be able to choose from among his own appointees. But if a vacancy opens up right away, the two most likely candidates are Judge Ketanji Brown Jackson, a federal district judge in DC, and Justice Leondra Kruger, who sits on the California Supreme Court.
</p>
<figure class="e-image">
<pre><code> &lt;img alt=" " src="https://cdn.vox-cdn.com/thumbor/dymRDm5dMIswEuKYyYx-YS4ylg4=/800x0/filters:no_upscale()/cdn.vox-cdn.com/uploads/chorus_asset/file/22216709/AP_795557115632.jpg" /&gt;
&lt;cite&gt;Rich Pedroncelli/AP&lt;/cite&gt;
&lt;figcaption&gt;Leondra Kruger is sworn in as an associate justice to the California Supreme Court by Gov. Jerry Brown in Sacramento, California, on January 5, 2015.&lt;/figcaption&gt;</code></pre>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="vbw5eS">
President Obama, it’s worth noting, interviewed Jackson for the nomination that eventually went to Garland, and Jackson clerked for Justice Breyer. Kruger clerked for the late Justice John Paul Stevens.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="FKwJQF">
But regardless of whom Biden might choose for an eventual Supreme Court vacancy, one of the most significant consequences of Warnock and Ossoff’s victories is that such a vacancy is now overwhelmingly likely to be filled. That wouldn’t be the case if McConnell were in charge.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="rSA3J4">
—<em>IM</em>
</p>
<h3 id="1XiKit">
Winner: More stimulus
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="4qSCoL">
President-elect Biden made additional coronavirus relief an explicit part of his pitch to Georgia voters earlier this week — and now that Democrats have won the Senate, more cash aid is far more likely to become a reality.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="z2ingq">
“By electing Jon and the reverend … [those <a href="https://www.vox.com/policy-and-politics/2020/12/28/22202986/stimulus-checks-house-vote-pelosi">$2,000 checks</a>] will go out the door immediately to people who are in real trouble,” Biden said while stumping on Ossoff’s and Warnock’s behalf on Tuesday. While it likely won’t be quite that straightforward, it is true that additional stimulus has a much better chance of getting approved with Democrats in control of the Senate.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="ydNf0h">
Thus far, Senate Majority Leader Mitch McConnell has prevented the $2,000 payments from advancing by tying them to a repeal of liability protections for tech companies and repeatedly blocking a standalone vote on them. With Republicans out of the majority come January 20 (when Kamala Harris can act as tie-breaker and elect Chuck Schumer as majority leader), McConnell won’t be able to set the Senate’s legislative agenda any longer.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="yjMA2L">
That change could well clear the path for another stimulus package: Democrats have emphasized, for instance, their support for larger checks as well as more state and local aid. And while they’ll still need some Republican backing if they go the route of a typical vote, they won’t have to contend with McConnell quashing the bill before it even gets to the floor.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="sWWebb">
—<em>Li Zhou</em>
</p>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Democrats win the Senate — by the slimmest margin possible</strong> -
<figure>
<img alt="" src="https://cdn.vox-cdn.com/thumbor/L5B8CTEV2BwQA6Yt1fiCWsX3xG0=/333x0:3000x2000/1310x983/cdn.vox-cdn.com/uploads/chorus_image/image/68626391/GettyImages_1230426653__2_.0.jpg"/>
<figcaption>
Jon Ossoff, left, and Rev. Raphael Warnock have both won their respective Senate races. | Jim Watson/AFP via Getty Images
</figcaption>
</figure></li>
</ul>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Democrats will hold the edge with a split Senate, giving them a shot at governing.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="FUBdEg">
Winning a pair of January 5 Senate runoffs in Georgia, Democrats have regained control of the US Senate, but just barely.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="KWKp0E">
By capturing Georgia’s Senate seats — an impressive feat few political observers thought likely after the November election — Democrats have given themselves the barest of Senate majorities. They are technically split 50-50 with Republicans, with Vice President-elect Kamala Harris serving as the tie-breaker for simple majority votes. Importantly, though, it will be Democrat Chuck Schumer, not Republican Mitch McConnell, who will hold the title of majority leader.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="G7sfSd">
Tuesday’s victory solidifies the party’s control of Congress as President-elect Joe Biden prepares to take office with an ambitious policy agenda. It guarantees Democrats will at least be able to decide what bills make it to the Senate floor, as well as be able to more easily confirm Biden’s Cabinet appointments and judicial nominees.
</p>
<figure class="e-image">
<pre><code> &lt;img alt=" " src="https://cdn.vox-cdn.com/thumbor/9Mhf_fC_Dxf_4oF86lXcnwjwkW8=/800x0/filters:no_upscale()/cdn.vox-cdn.com/uploads/chorus_asset/file/22216353/GettyImages_1294511866.jpg" /&gt;
&lt;cite&gt;Chip Somodevilla/Getty Images&lt;/cite&gt;
&lt;figcaption&gt;President-elect Joe Biden campaigns with Jon Ossoff, left, and Rev. Raphael Warnock in Atlanta, Georgia, on January 4.&lt;/figcaption&gt;</code></pre>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="gvKsBi">
Still, Democrats will have to get buy-in from at least 10 additional Republican senators in order to clear the 60-vote threshold needed to pass most major bills. They may be able to work around the filibuster in <a href="https://www.vox.com/21499869/joe-biden-stimulus-reconciliation"><strong>budget reconciliation bills</strong></a>, but getting broad bipartisan support to pass most legislation will be unavoidable.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="fOws2x">
Senate Democrats and Biden clearly see their first priorities as trying to curb the spread of Covid-19 with additional relief and funding for vaccine distribution and a more coordinated federal and state response to the pandemic. Economic recovery is another immediate priority, which could include an infrastructure package.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="rF7GBN">
“We feel a great sense of responsibility and a great sense of urgency,” Sen. Debbie Stabenow (D-MI), chair of the Senate Democratic Policy and Communications Committee, told Vox last fall. “There’s so much that has to be rebuilt and repaired, but it has to start with getting our arms around this once-in-a-generation pandemic.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="r3JSic">
Infrastructure could be one of the few opportunities for bipartisanship; a number of moderate Republicans are willing to work on such a bill, but other Republicans have already begun to raise concerns about the national deficit and additional spending after themselves passing a massive tax cut in 2017 that ballooned the deficit. Still, Biden, who served as a senator for decades before becoming Obama’s vice president, has a long working relationship with McConnell in the Senate. This could prove to be an asset going into his presidency.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="LDjbGf">
“President-elect Biden, one of his strengths is reaching out and finding common ground,” Phil Schiliro, who served as President Barack Obama’s legislative director, told Vox. Schiliro added that Biden and McConnell “have a shared experience and history in the Senate; they have a shared respect for the Senate, and I think that’s helpful.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="vyMoA9">
Realistically, the likelier scenario for a closely divided Senate is more partisan gridlock.
</p>
<h3 id="zDu1OW">
What Democrats want to do
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="6ar01m">
Democrats widely agree a new Covid-19 relief and response package should be their first priority. A new bill would likely be modeled on the House-passed <a href="https://www.vox.com/2020/5/12/21254397/next-coronavirus-stimulus-package-democrats-heroes-act">HEROES Act</a>, which included $75 million for testing and contact tracing, “strike teams” to tackle challenges around long-term care and prisons, and funding to help cash-strapped state and local governments.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="NcCkmC">
Next, Democrats say they want to deal with the stagnating economy. Biden has released a <a href="https://joebiden.com/climate-plan/">$2 trillion green jobs plan</a>, aiming to create millions of jobs through green infrastructure, retrofitting houses, and manufacturing electric cars, among other things. There are a number of ways Biden’s White House can work on achieving these goals, but he needs Congress to fully realize it.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="rbfOmV">
“In addition to fighting and containing the coronavirus, we will work aggressively to create jobs and improve the unemployment crisis caused by President Trump,” Senate Minority Leader Chuck Schumer told Vox in a statement earlier this fall.
</p>
<figure class="e-image">
<pre><code> &lt;img alt=" " src="https://cdn.vox-cdn.com/thumbor/0MMFaPdUGTrjkH3J6AFdywvuBI0=/800x0/filters:no_upscale()/cdn.vox-cdn.com/uploads/chorus_asset/file/22216383/GettyImages_1291495701.jpg" /&gt;
&lt;cite&gt;Tasos Katopodis/Getty Images&lt;/cite&gt;
&lt;figcaption&gt;Senate Minority Leader Chuck Schumer participates in ongoing talks for the Covid-19 relief bill on December 15, 2020.&lt;/figcaption&gt;</code></pre>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="0XgOAw">
Biden shares the broad goal of getting the United States to net-zero emissions by 2050, but he’s also set more aggressive targets, like getting to <a href="https://www.nbcnews.com/science/environment/how-biden-s-climate-plan-makes-clean-energy-2035-very-n1234528">100 percent clean electricity</a> in the US by 2035. House Democrats also <a href="https://www.washingtonpost.com/local/trafficandcommuting/house-passes-15-trillion-infrastructure-bill/2020/07/01/6a0a19e8-bbe6-11ea-80b9-40ece9a701dc_story.html">passed a $1.5 trillion infrastructure bill</a> in July, which could be merged with Biden’s climate plan.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="dw7Y1Y">
Democrats will likely push for a climate component in any future infrastructure package, but Republicans may balk at that idea and push for a more targeted bill.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="eUKE0Z">
Democrats have a long wish list of other priorities including anti-corruption reforms and legislation to expand voting rights (which, again, is the first bill that will be taken up by the US House), policing reforms, and a public option to expand access to health care as well as immigration reform and universal background checks for guns.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="9T0XfF">
Many of these will have to be put on the back burner for now, as Democrats have limited political capital — and the thinnest possible majority to do anything.
</p>
<h3 id="WQz0Eb">
Senate Democrats and the filibuster
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="YVSRY4">
Once again, Democrats fall short of the filibuster-proof 60-vote Senate majority — by a whopping 10 votes.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="fJrlZz">
The last time Democrats won a majority in the Senate was in 2008, when they rode Obama’s coattails to victory. They had 59 votes in the Senate, far more than Democrats do now.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="ZhH7VF">
Obama was able to pull over a few Republican Senate votes in 2009 to pass the American Recovery and Reinvestment Act after the 2008 financial crisis. But on many other legislative priorities, McConnell’s Republican minority threw up a 60-vote barrier to passing most Democratic legislation.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="m2m9Th">
McConnell admitted two years into the Obama era that he had <a href="https://www.washingtonpost.com/news/fact-checker/wp/2017/01/11/when-did-mitch-mcconnell-say-he-wanted-to-make-obama-a-one-term-president/">planned</a> to do everything he could to ensure the Obama presidency was “one term.” The former president wrote in his new memoir that the filibuster “would prove to be the most chronic political headache of my presidency.”
</p>
<figure class="e-image">
<pre><code> &lt;img alt=" " src="https://cdn.vox-cdn.com/thumbor/J0-AhoE2IWKzvFEBajYH_XW5MR0=/800x0/filters:no_upscale()/cdn.vox-cdn.com/uploads/chorus_asset/file/22216358/GettyImages_1230409572.jpg" /&gt;
&lt;cite&gt;Kevin Dietsch/AFP via Getty Images&lt;/cite&gt;
&lt;figcaption&gt;Senate Majority Leader Mitch McConnell participates in a mock swearing-in for the 117th Congress with Vice President Mike Pence on January 3.&lt;/figcaption&gt;</code></pre>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="iVlv7k">
“With President Obama, no matter how much outreach he tried to do with Congressional Republicans, there seemed to be absolutely no interest and no acceptance with what he was trying to do,” Schiliro said. “If congressional Republicans take that approach this time, it will be very difficult to get anything done.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="FyND3B">
Democrats have a few options with 51 votes: attempt to work with Republicans on bipartisan issues, or pass big items through a process known as budget reconciliation that only requires a simple majority. Much less likely is blowing up the Senate filibuster. Doing so would require 51 votes, but moderate Democrats like Sen. Joe Manchin (WV) have unequivocally said they’re opposed.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="OzdiUm">
“That would break the Senate,” Manchin told the <a href="https://www.nytimes.com/2020/11/30/us/politics/joe-manchin-interview.html?smid=tw-share"><strong>New York Times’s Luke Broadwater recently</strong></a>. “If you basically do away with the filibuster altogether for legislation, you won’t have the Senate. You’re a glorified House. And I will not do that.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="iT1DyH">
Still, some Democrats may continue to push for filibuster elimination or reform by a simple majority. Their argument? Don’t assume Senate Republicans are going to do the right thing.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="UZvQ59">
“Basically, every member of the conference is concerned about not letting McConnell paralyze the place,” Sen. Jeff Merkley (D-OR), the Democrat leading talks about filibuster reform, told Vox earlier this year.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="mHeZaN">
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="DWPVRP">
</p>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Jon Ossoff beats Sen. David Perdue, handing Democrats control of the Senate</strong> -
<figure>
<img alt="" src="https://cdn.vox-cdn.com/thumbor/4sBhV1CumdQ_8uBzbtVc8j0ZxqQ=/0x0:2668x2001/1310x983/cdn.vox-cdn.com/uploads/chorus_image/image/68626389/GettyImages_1294161257.0.jpg"/>
<figcaption>
Jon Ossoff greets a supporter during a campaign stop outside Athens-Clarke County City Hall on January 2. | Alex Wong/Getty Images
</figcaption>
</figure></li>
</ul>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Ossoff’s win in Georgia is crucial for Democrats.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="awLtMN">
Democrat Jon Ossoff has won a Georgia Senate seat, beating Republican David Perdue in one of the state’s pivotal runoffs on Tuesday.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="zofCpQ">
The race was called by Vox’s elections partner Decision Desk at 2:14 am ET.
</p>
<div id="eON6wF">
<blockquote class="twitter-tweet">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" dir="ltr" lang="en">
Decision Desk HQ projects <a href="https://twitter.com/ossoff?ref_src=twsrc%5Etfw"><span class="citation">@ossoff</span></a> (D) has won the Georgia Regular Senate Runoff Election, giving Democrats control of the Senate on January 20th. <br/> <br/>Race Called: 2:14AM EST 01.06.21<br/> <br/>All Results: <a href="https://t.co/AOgwtoMxNF">https://t.co/AOgwtoMxNF</a>
</p>
— Decision Desk HQ (<span class="citation">@DecisionDeskHQ</span>) <a href="https://twitter.com/DecisionDeskHQ/status/1346716886340411392?ref_src=twsrc%5Etfw">January 6, 2021</a>
</blockquote>
</div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="a9IJ7f">
Ossoff is the second Georgia Democrat to win in the January 5 runoff election. Democrat Rev. <a href="https://www.vox.com/2021/1/5/22213432/warnock-beats-loeffler-georgia-senate-special-election">Raphael Warnock also won</a> his race late on Tuesday night, per a call from Vox’s elections partner Decision Desk. Crucially, Ossoff’s victory means Democrats have now won the two seats required to retake control of the Senate.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="t2pn5Z">
Ossoff is a former investigative journalist who ran for Congress in Georgia’s Sixth Congressional District in 2017, <a href="https://www.nytimes.com/elections/results/georgia-congressional-runoff-ossoff-handel"><strong>narrowly losing</strong></a> to Republican Karen Handel in a runoff. Few elections experts in Georgia predicted he would beat Perdue, given the Democrat fell about 88,000 votes behind Perdue in November. Ossoff’s win two months later suggests higher enthusiasm for Democratic candidates and weaker enthusiasm for Republicans.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="nfyXcZ">
Ossoff and Warnock’s victories come on the heels of President-elect Joe Biden being the first Democratic presidential candidate to win Georgia since 1992. House Democrats also flipped their only GOP-held district of 2020 in Georgia’s Seventh Congressional District, in Atlanta’s suburbs.
</p>
<aside id="o3BLPb">
<div>
</div>
</aside>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Y88c0o">
These big wins for Democrats signify a shift in Georgia’s diversifying electorate.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="acjELk">
“The state is becoming younger and more diverse every day,” Ossoff <a href="https://www.vox.com/21536826/georgia-senate-race-ossoff-loeffler-warnock-perdue">told Vox in an interview this fall</a>. “The investment in Democratic infrastructure over the last decade has been massive.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="gF4Yha">
Ossoff’s win is also a firm rebuke of President Donald Trump in a Senate race that the outgoing president made largely about him and his November loss in Georgia. Ossoff’s Republican opponent, Perdue, was <a href="https://www.ajc.com/politics/perdues-embrace-of-trump-boosts-complicates-reelection-bid/EMHB3E45IZGDPCA2EC47CG4FGU/">one of Trump’s earliest allies in the Senate</a>, and a staunch defender of the president after the November 3 election. Perdue and fellow Republican Sen. Kelly Loeffler backed Trump in his battle with Georgia Republican state officials, counting on the president’s support in the state to power them to victory.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="fQC0gc">
That support ultimately didn’t materialize.
</p>
<h3 id="kht7ld">
What Ossoff’s win means for Senate control and Biden’s agenda
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="OZxTiK">
Joe Biden may have won the presidency on November 3, but he doesn’t have much chance to deliver on the bold agenda he’s proposed without buy-in from Congress.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="gYLVUB">
Biden is entering office facing multiple crises: The Covid-19 pandemic is worsening in the US even as vaccines start to be delivered across the country, and there are <a href="https://www.theguardian.com/business/2020/dec/31/us-unemployment-december-coronavirus">still millions out of work</a> due to coronavirus-related layoffs. After months of partisan gridlock, Congress managed to pass a $900 billion economic relief package before the new year. Biden has said he wants more economic stimulus, but whether a future package can pass will largely be determined by which party controls the Senate.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="OnFbKJ">
“The power is literally in your hands. Unlike any time in my career, one state can chart the course — not just for the next four years, but for the next generation,” Biden said at a Monday rally in support of Ossoff and Warnock.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="AcDvYQ">
Even with this victory, Democrats will have to contend with Senate Republicans. Securing both Georgia seats gives Democrats 50 seats in the Senate, plus Vice President-elect Kamala Harris serving as a crucial tie-breaker for simple majority votes. The catch is that most bills need to clear a 60-vote supermajority in the Senate. Therefore, even if Democrats have control of the Senate, they will generally need around 10 Republican votes to get things done.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="yyfaS9">
Passing Democratic bills will be extremely difficult in a 50-50 Senate. It will be tough to even pass broad bipartisan bills. But winning Georgia’s seats is the only thing that guarantees that Democrats — rather than McConnell — will have a say on which bills come to the Senate floor for debate. It would also give them the ability to more easily confirm Biden’s Cabinet picks, or his nominees to the federal judiciary and US Supreme Court.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="lzXdSi">
Ossoff’s win in Georgia ensures Democrats can at least count on that razor-thin Senate majority.
</p>
<h1 data-aos="fade-right" id="from-the-hindu-sports">From The Hindu: Sports</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Australia vs India preview | Rohit Sharma to open, Navdeep Saini to debut in Sydney Test</strong> - Australia are literally pushing a 70% fit David Warner out there in the middle to combat fire with fire even as his statements make it clear that he is not at all comfortable with the idea</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Australia vs India: Claire Polosak set to become first female match official in men's Test match</strong> - The 32-year-old from New South Wales has already earned the distinction of being the first female match official in a men's List A game in Australia</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Pravin Amre joins Delhi Capitals as assistant coach</strong> - Amre, who served as the franchise's head talent scout between 2014-2019, will join the existing coaching staff, headed by Ricky Ponting</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Hotel quarantine in "normal" Sydney is challenging but we are not annoyed: Rahane</strong> - “We know how to handle it and we are prepared for any kind of situation.”</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>One fan at MCG tests positive for COVID-19; others advised to get tested and isolate</strong> - The State health authorities said the man in his thirties was not infectious while at the famed Melbourne Cricket Ground on the second day of play.</p></li>
</ul>
<h1 data-aos="fade-right" id="from-the-hindu-national-news">From The Hindu: National News</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Actor Radhika and her brother under CCB’s scanner</strong> - Duo had financial transactions with a conman claiming to have connections with a right-wing organisation</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The perfect New Year gift</strong> - A huge tank in Tarikere is cleared of garbage and weeds and opened to the public</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Bar Headed Goose and its strong link with Pong Dam Lake in Himachal</strong> - In an unfolding avian-flu crisis, a substantial number of this high-altitude bird which descends on this wetland every winter and adds to its charm have perished along with other bird species</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Congress, AAP in war of words over farm laws</strong> - Food Minister’s statement mischievously twisted, says Amarinder Singh</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Budaun gang rape | National Commission for Women seeks U.P. police intervention in case</strong> - The National Commission for Women (NCW) has sought immediate intervention of the U.P. police in the matter of the alleged gang rape and murder of a 50</p></li>
</ul>
<h1 data-aos="fade-right" id="from-bbc-europe">From BBC: Europe</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Covid: England's third national lockdown legally comes into force</strong> - MPs will debate and retrospectively vote on the new measures later amid surging coronavirus cases.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Covid-19: UK daily coronavirus cases top 60,000 for first time</strong> - Roughly one in 50 people in England has got the virus, Prof Chris Whitty says.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Albert Roux: Chef and culinary 'legend' dies aged 85</strong> - Gordon Ramsay remembers late chef Albert Roux as "the man who installed gastronomy in Britain".</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Virgin joins Tui and Thomas Cook in cancelling holiday bookings</strong> - Virgin Holidays joins Tui and Thomas Cook in cancelling holidays after latest coronavirus restrictions.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Music festivals could be cancelled this month, MPs told</strong> - Organisers are facing "dire straits" if the 2021 music festival season is scrapped, MPs are told.</p></li>
</ul>
<h1 data-aos="fade-right" id="from-ars-technica">From Ars Technica</h1>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Bucking Trump, NSA and FBI say Russia was “likely” behind SolarWinds hack</strong> - Trump has downplayed the mass compromise and Russia's involvement. Underlings disagree. - <a href="https://arstechnica.com/?p=1733205">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>In a parting gift, EPA finalizes rules to limit its use of science</strong> - On its way out, the Trump administration makes things harder for the next one. - <a href="https://arstechnica.com/?p=1733176">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Court says Uber can’t hold users to terms they probably didn’t read</strong> - Adding a link to a registration page isn't good enough, court says. - <a href="https://arstechnica.com/?p=1733028">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>This P2P car-sharing company has a plan to boost Black entrepreneurship</strong> - Turo partners with Kiva to provide interest-free loans to an underserved community. - <a href="https://arstechnica.com/?p=1733136">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Telegram feature exposes your precise address to hackers</strong> - Messenger maker has expressed no plans to fix location disclosure flaw. - <a href="https://arstechnica.com/?p=1733117">link</a></p></li>
</ul>
<h1 data-aos="fade-right" id="from-jokes-subreddit">From Jokes Subreddit</h1>
<ul>
<li><strong>Cancer!</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Karen: Doctor, I've not been feeling well lately
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Doctor: Well, I've looked at your lab reports and I'm afraid I have some bad news...
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Karen: Don't give me this lab nonsense, you bureaucratic paper pusher! I don't believe Western medicine anyways! I've been following homeopathic medicine, faith-based approaches, and healing crystals all my life, and they never let me down. Now, will you do things my way, or do I need to talk to the hospital management?
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Doctor: Sure, sure, lady. We'll do things your way. Does an astrology-based approach work for you?
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Karen: That's better! Of course, it would!
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Doctor: What's your birth sign?
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Karen: Cancer.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Doctor: Well what a fucking coincidence.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
PS: it's my Cake day, I am Cancer (July), I am a doctor, I hate quacks! It fits.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Edit: oh my! Thank you so much kind people! This is the first time I got awards and so many upvotes. You made my day!!
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/sajanacharya"> /u/sajanacharya </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/kre2gn/cancer/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/kre2gn/cancer/">[comments]</a></span></p></li>
<li><strong>How Long?</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
This guy sticks his head into a barbershop and asks, "How long before I can get a haircut?"
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The barber looks around the shop and says, "About two hours."
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The guy leaves.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
A few days later the same guy sticks his head in the door and asks, "How long before I can get a haircut?"
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The barber looks around at his shop full of customers and says, "About two hours."
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The guy leaves.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
A week later the same guy sticks his head in the shop and asks, "How long before I can get a haircut?"
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The barber looks around the shop and says, "About an hour and a half."
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The guy leaves.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The barber looks over at a friend in the shop and says, "Hey, Bill, follow that guy and see where he goes."
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
In a little while, Bill comes back into the shop laughing hysterically.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The barber asks, "Bill, where did that guy go when he left here?"
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Bill looks at him and says, "To your house."
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/rnicholson77"> /u/rnicholson77 </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/kr0az3/how_long/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/kr0az3/how_long/">[comments]</a></span></p></li>
<li><strong>A lot of people are roasting Cleaver on saying "Awoman"...</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
I mean, I know that "Amen" comes from Hebrew and means "so be it", and therefore "Awoman" would make no sense in Hebrew.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
In Shebrew, however, it makes complete sense!!!
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/Moerox111"> /u/Moerox111 </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/kr8tbt/a_lot_of_people_are_roasting_cleaver_on_saying/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/kr8tbt/a_lot_of_people_are_roasting_cleaver_on_saying/">[comments]</a></span></p></li>
<li><strong>A boy is selling fish on a corner.</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
To get his customers' attention, he begins yelling, "Dam fish for sale! Get your dam fish here!"
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
A pastor hears this and asks, "Why are you calling them 'dam fish.'" The boy responds, "Because I caught these fish at the local dam." The pastor buys a couple fish, takes them home to his wife, and asks her to cook the dam fish.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The wife responds surprised, "I didn't know it was acceptable for a preacher to speak that way." He explains to her why they are dam fish.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Later at the dinner table, he asks his son to pass the dam fish. He responds, "That's the spirit, Dad! Now pass the f*cking potatoes!"
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/esc1999"> /u/esc1999 </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/kquaxq/a_boy_is_selling_fish_on_a_corner/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/kquaxq/a_boy_is_selling_fish_on_a_corner/">[comments]</a></span></p></li>
<li><strong>If we're saying Amen and Awomen now...</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Are we going to start having to sing hymns and herns?
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Edit: hers to herns per a great suggestion
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/Doctah_Feelgood"> /u/Doctah_Feelgood </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/kr0rht/if_were_saying_amen_and_awomen_now/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/kr0rht/if_were_saying_amen_and_awomen_now/">[comments]</a></span></p></li>
</ul>
<script>AOS.init();</script></body></html>

4
index.html
View File

@ -13,9 +13,9 @@ Archive | Daily Reports
<li> <a href="#covid-19">Covid-19</a>
</li></li></ul>
<h2 id="daily-dose">Daily Dose</h2>
<ul id="daily-dose-list"><li><a href="./archive-daily-dose/05 January, 2021.html">05 January, 2021</a></li><li><a href="./archive-daily-dose/04 January, 2021.html">04 January, 2021</a></li><li><a href="./archive-daily-dose/03 January, 2021.html">03 January, 2021</a></li><li><a href="./archive-daily-dose/02 January, 2021.html">02 January, 2021</a></li><li><a href="./archive-daily-dose/01 January, 2021.html">01 January, 2021</a></li><li><a href="./archive-daily-dose/31 December, 2020.html">31 December, 2020</a></li><li><a href="./archive-daily-dose/30 December, 2020.html">30 December, 2020</a></li><li><a href="./archive-daily-dose/29 December, 2020.html">29 December, 2020</a></li><li><a href="./archive-daily-dose/28 December, 2020.html">28 December, 2020</a></li><li><a href="./archive-daily-dose/27 December, 2020.html">27 December, 2020</a></li><li><a href="./archive-daily-dose/26 December, 2020.html">26 December, 2020</a></li><li><a href="./archive-daily-dose/25 December, 2020.html">25 December, 2020</a></li><li><a href="./archive-daily-dose/24 December, 2020.html">24 December, 2020</a></li><li><a href="./archive-daily-dose/23 December, 2020.html">23 December, 2020</a></li><li><a href="./archive-daily-dose/22 December, 2020.html">22 December, 2020</a></li><li><a href="./archive-daily-dose/21 December, 2020.html">21 December, 2020</a></li><li><a href="./archive-daily-dose/20 December, 2020.html">20 December, 2020</a></li><li><a href="./archive-daily-dose/19 December, 2020.html">19 December, 2020</a></li><li><a href="./archive-daily-dose/18 December, 2020.html">18 December, 2020</a></li><li><a href="./archive-daily-dose/17 December, 2020.html">17 December, 2020</a></li><li><a href="./archive-daily-dose/16 December, 2020.html">16 December, 2020</a></li><li><a href="./archive-daily-dose/15 December, 2020.html">15 December, 2020</a></li><li><a href="./archive-daily-dose/14 December, 2020.html">14 December, 2020</a></li><li><a href="./archive-daily-dose/13 December, 2020.html">13 December, 2020</a></li><li><a href="./archive-daily-dose/12 December, 2020.html">12 December, 2020</a></li><li><a href="./archive-daily-dose/11 December, 2020.html">11 December, 2020</a></li><li><a href="./archive-daily-dose/10 December, 2020.html">10 December, 2020</a></li><li><a href="./archive-daily-dose/09 December, 2020.html">09 December, 2020</a></li><li><a href="./archive-daily-dose/08 December, 2020.html">08 December, 2020</a></li><li><a href="./archive-daily-dose/07 December, 2020.html">07 December, 2020</a></li><li><a href="./archive-daily-dose/06 December, 2020.html">06 December, 2020</a></li><li><a href="./archive-daily-dose/05 December, 2020.html">05 December, 2020</a></li><li><a href="./archive-daily-dose/04 December, 2020.html">04 December, 2020</a></li><li><a href="./archive-daily-dose/03 December, 2020.html">03 December, 2020</a></li><li><a href="./archive-daily-dose/02 December, 2020.html">02 December, 2020</a></li><li><a href="./archive-daily-dose/01 December, 2020.html">01 December, 2020</a></li><li><a href="./archive-daily-dose/30 November, 2020.html">30 November, 2020</a></li><li><a href="./archive-daily-dose/29 November, 2020.html">29 November, 2020</a></li><li><a href="./archive-daily-dose/28 November, 2020.html">28 November, 2020</a></li><li><a href="./archive-daily-dose/27 November, 2020.html">27 November, 2020</a></li><li><a href="./archive-daily-dose/26 November, 2020.html">26 November, 2020</a></li><li><a href="./archive-daily-dose/25 November, 2020.html">25 November, 2020</a></li><li><a href="./archive-daily-dose/24 November, 2020.html">24 November, 2020</a></li><li><a href="./archive-daily-dose/23 November, 2020.html">23 November, 2020</a></li><li><a href="./archive-daily-dose/22 November, 2020.html">22 November, 2020</a></li><li><a href="./archive-daily-dose/21 November, 2020.html">21 November, 2020</a></li><li><a href="./archive-daily-dose/20 November, 2020.html">20 November, 2020</a></li><li><a href="./archive-daily-dose/19 November, 2020.html">19 November, 2020</a></li><li><a href="./archive-daily-dose/18 November, 2020.html">18 November, 2020</a></li><li><a href="./archive-daily-dose/17 November, 2020.html">17 November, 2020</a></li><li><a href="./archive-daily-dose/16 November, 2020.html">16 November, 2020</a></li><li><a href="./archive-daily-dose/15 November, 2020.html">15 November, 2020</a></li><li><a href="./archive-daily-dose/14 November, 2020.html">14 November, 2020</a></li><li><a href="./archive-daily-dose/13 November, 2020.html">13 November, 2020</a></li><li><a href="./archive-daily-dose/12 November, 2020.html">12 November, 2020</a></li><li><a href="./archive-daily-dose/11 November, 2020.html">11 November, 2020</a></li>
<ul id="daily-dose-list"><li><a href="./archive-daily-dose/06 January, 2021.html">06 January, 2021</a></li><li><a href="./archive-daily-dose/05 January, 2021.html">05 January, 2021</a></li><li><a href="./archive-daily-dose/04 January, 2021.html">04 January, 2021</a></li><li><a href="./archive-daily-dose/03 January, 2021.html">03 January, 2021</a></li><li><a href="./archive-daily-dose/02 January, 2021.html">02 January, 2021</a></li><li><a href="./archive-daily-dose/01 January, 2021.html">01 January, 2021</a></li><li><a href="./archive-daily-dose/31 December, 2020.html">31 December, 2020</a></li><li><a href="./archive-daily-dose/30 December, 2020.html">30 December, 2020</a></li><li><a href="./archive-daily-dose/29 December, 2020.html">29 December, 2020</a></li><li><a href="./archive-daily-dose/28 December, 2020.html">28 December, 2020</a></li><li><a href="./archive-daily-dose/27 December, 2020.html">27 December, 2020</a></li><li><a href="./archive-daily-dose/26 December, 2020.html">26 December, 2020</a></li><li><a href="./archive-daily-dose/25 December, 2020.html">25 December, 2020</a></li><li><a href="./archive-daily-dose/24 December, 2020.html">24 December, 2020</a></li><li><a href="./archive-daily-dose/23 December, 2020.html">23 December, 2020</a></li><li><a href="./archive-daily-dose/22 December, 2020.html">22 December, 2020</a></li><li><a href="./archive-daily-dose/21 December, 2020.html">21 December, 2020</a></li><li><a href="./archive-daily-dose/20 December, 2020.html">20 December, 2020</a></li><li><a href="./archive-daily-dose/19 December, 2020.html">19 December, 2020</a></li><li><a href="./archive-daily-dose/18 December, 2020.html">18 December, 2020</a></li><li><a href="./archive-daily-dose/17 December, 2020.html">17 December, 2020</a></li><li><a href="./archive-daily-dose/16 December, 2020.html">16 December, 2020</a></li><li><a href="./archive-daily-dose/15 December, 2020.html">15 December, 2020</a></li><li><a href="./archive-daily-dose/14 December, 2020.html">14 December, 2020</a></li><li><a href="./archive-daily-dose/13 December, 2020.html">13 December, 2020</a></li><li><a href="./archive-daily-dose/12 December, 2020.html">12 December, 2020</a></li><li><a href="./archive-daily-dose/11 December, 2020.html">11 December, 2020</a></li><li><a href="./archive-daily-dose/10 December, 2020.html">10 December, 2020</a></li><li><a href="./archive-daily-dose/09 December, 2020.html">09 December, 2020</a></li><li><a href="./archive-daily-dose/08 December, 2020.html">08 December, 2020</a></li><li><a href="./archive-daily-dose/07 December, 2020.html">07 December, 2020</a></li><li><a href="./archive-daily-dose/06 December, 2020.html">06 December, 2020</a></li><li><a href="./archive-daily-dose/05 December, 2020.html">05 December, 2020</a></li><li><a href="./archive-daily-dose/04 December, 2020.html">04 December, 2020</a></li><li><a href="./archive-daily-dose/03 December, 2020.html">03 December, 2020</a></li><li><a href="./archive-daily-dose/02 December, 2020.html">02 December, 2020</a></li><li><a href="./archive-daily-dose/01 December, 2020.html">01 December, 2020</a></li><li><a href="./archive-daily-dose/30 November, 2020.html">30 November, 2020</a></li><li><a href="./archive-daily-dose/29 November, 2020.html">29 November, 2020</a></li><li><a href="./archive-daily-dose/28 November, 2020.html">28 November, 2020</a></li><li><a href="./archive-daily-dose/27 November, 2020.html">27 November, 2020</a></li><li><a href="./archive-daily-dose/26 November, 2020.html">26 November, 2020</a></li><li><a href="./archive-daily-dose/25 November, 2020.html">25 November, 2020</a></li><li><a href="./archive-daily-dose/24 November, 2020.html">24 November, 2020</a></li><li><a href="./archive-daily-dose/23 November, 2020.html">23 November, 2020</a></li><li><a href="./archive-daily-dose/22 November, 2020.html">22 November, 2020</a></li><li><a href="./archive-daily-dose/21 November, 2020.html">21 November, 2020</a></li><li><a href="./archive-daily-dose/20 November, 2020.html">20 November, 2020</a></li><li><a href="./archive-daily-dose/19 November, 2020.html">19 November, 2020</a></li><li><a href="./archive-daily-dose/18 November, 2020.html">18 November, 2020</a></li><li><a href="./archive-daily-dose/17 November, 2020.html">17 November, 2020</a></li><li><a href="./archive-daily-dose/16 November, 2020.html">16 November, 2020</a></li><li><a href="./archive-daily-dose/15 November, 2020.html">15 November, 2020</a></li><li><a href="./archive-daily-dose/14 November, 2020.html">14 November, 2020</a></li><li><a href="./archive-daily-dose/13 November, 2020.html">13 November, 2020</a></li><li><a href="./archive-daily-dose/12 November, 2020.html">12 November, 2020</a></li><li><a href="./archive-daily-dose/11 November, 2020.html">11 November, 2020</a></li>
</ul>
<h2 id="covid-19">Covid-19</h2>
<ul id="covid-19-list"><li><a href="./archive-covid-19/05 January, 2021.html">05 January, 2021</a></li><li><a href="./archive-covid-19/04 January, 2021.html">04 January, 2021</a></li><li><a href="./archive-covid-19/03 January, 2021.html">03 January, 2021</a></li><li><a href="./archive-covid-19/02 January, 2021.html">02 January, 2021</a></li><li><a href="./archive-covid-19/01 January, 2021.html">01 January, 2021</a></li><li><a href="./archive-covid-19/31 December, 2020.html">31 December, 2020</a></li><li><a href="./archive-covid-19/30 December, 2020.html">30 December, 2020</a></li><li><a href="./archive-covid-19/29 December, 2020.html">29 December, 2020</a></li><li><a href="./archive-covid-19/28 December, 2020.html">28 December, 2020</a></li><li><a href="./archive-covid-19/27 December, 2020.html">27 December, 2020</a></li><li><a href="./archive-covid-19/26 December, 2020.html">26 December, 2020</a></li><li><a href="./archive-covid-19/25 December, 2020.html">25 December, 2020</a></li><li><a href="./archive-covid-19/24 December, 2020.html">24 December, 2020</a></li><li><a href="./archive-covid-19/23 December, 2020.html">23 December, 2020</a></li><li><a href="./archive-covid-19/22 December, 2020.html">22 December, 2020</a></li><li><a href="./archive-covid-19/21 December, 2020.html">21 December, 2020</a></li><li><a href="./archive-covid-19/20 December, 2020.html">20 December, 2020</a></li><li><a href="./archive-covid-19/19 December, 2020.html">19 December, 2020</a></li><li><a href="./archive-covid-19/18 December, 2020.html">18 December, 2020</a></li><li><a href="./archive-covid-19/17 December, 2020.html">17 December, 2020</a></li><li><a href="./archive-covid-19/16 December, 2020.html">16 December, 2020</a></li><li><a href="./archive-covid-19/15 December, 2020.html">15 December, 2020</a></li><li><a href="./archive-covid-19/14 December, 2020.html">14 December, 2020</a></li><li><a href="./archive-covid-19/13 December, 2020.html">13 December, 2020</a></li><li><a href="./archive-covid-19/12 December, 2020.html">12 December, 2020</a></li><li><a href="./archive-covid-19/11 December, 2020.html">11 December, 2020</a></li><li><a href="./archive-covid-19/10 December, 2020.html">10 December, 2020</a></li><li><a href="./archive-covid-19/09 December, 2020.html">09 December, 2020</a></li><li><a href="./archive-covid-19/08 December, 2020.html">08 December, 2020</a></li><li><a href="./archive-covid-19/07 December, 2020.html">07 December, 2020</a></li><li><a href="./archive-covid-19/06 December, 2020.html">06 December, 2020</a></li><li><a href="./archive-covid-19/05 December, 2020.html">05 December, 2020</a></li><li><a href="./archive-covid-19/04 December, 2020.html">04 December, 2020</a></li><li><a href="./archive-covid-19/03 December, 2020.html">03 December, 2020</a></li><li><a href="./archive-covid-19/02 December, 2020.html">02 December, 2020</a></li><li><a href="./archive-covid-19/01 December, 2020.html">01 December, 2020</a></li><li><a href="./archive-covid-19/30 November, 2020.html">30 November, 2020</a></li><li><a href="./archive-covid-19/29 November, 2020.html">29 November, 2020</a></li><li><a href="./archive-covid-19/28 November, 2020.html">28 November, 2020</a></li><li><a href="./archive-covid-19/27 November, 2020.html">27 November, 2020</a></li><li><a href="./archive-covid-19/26 November, 2020.html">26 November, 2020</a></li><li><a href="./archive-covid-19/25 November, 2020.html">25 November, 2020</a></li><li><a href="./archive-covid-19/24 November, 2020.html">24 November, 2020</a></li><li><a href="./archive-covid-19/23 November, 2020.html">23 November, 2020</a></li><li><a href="./archive-covid-19/22 November, 2020.html">22 November, 2020</a></li><li><a href="./archive-covid-19/21 November, 2020.html">21 November, 2020</a></li><li><a href="./archive-covid-19/20 November, 2020.html">20 November, 2020</a></li><li><a href="./archive-covid-19/19 November, 2020.html">19 November, 2020</a></li><li><a href="./archive-covid-19/18 November, 2020.html">18 November, 2020</a></li><li><a href="./archive-covid-19/17 November, 2020.html">17 November, 2020</a></li><li><a href="./archive-covid-19/16 November, 2020.html">16 November, 2020</a></li><li><a href="./archive-covid-19/15 November, 2020.html">15 November, 2020</a></li><li><a href="./archive-covid-19/14 November, 2020.html">14 November, 2020</a></li><li><a href="./archive-covid-19/13 November, 2020.html">13 November, 2020</a></li><li><a href="./archive-covid-19/12 November, 2020.html">12 November, 2020</a></li><li><a href="./archive-covid-19/11 November, 2020.html">11 November, 2020</a></li>
<ul id="covid-19-list"><li><a href="./archive-covid-19/06 January, 2021.html">06 January, 2021</a></li><li><a href="./archive-covid-19/05 January, 2021.html">05 January, 2021</a></li><li><a href="./archive-covid-19/04 January, 2021.html">04 January, 2021</a></li><li><a href="./archive-covid-19/03 January, 2021.html">03 January, 2021</a></li><li><a href="./archive-covid-19/02 January, 2021.html">02 January, 2021</a></li><li><a href="./archive-covid-19/01 January, 2021.html">01 January, 2021</a></li><li><a href="./archive-covid-19/31 December, 2020.html">31 December, 2020</a></li><li><a href="./archive-covid-19/30 December, 2020.html">30 December, 2020</a></li><li><a href="./archive-covid-19/29 December, 2020.html">29 December, 2020</a></li><li><a href="./archive-covid-19/28 December, 2020.html">28 December, 2020</a></li><li><a href="./archive-covid-19/27 December, 2020.html">27 December, 2020</a></li><li><a href="./archive-covid-19/26 December, 2020.html">26 December, 2020</a></li><li><a href="./archive-covid-19/25 December, 2020.html">25 December, 2020</a></li><li><a href="./archive-covid-19/24 December, 2020.html">24 December, 2020</a></li><li><a href="./archive-covid-19/23 December, 2020.html">23 December, 2020</a></li><li><a href="./archive-covid-19/22 December, 2020.html">22 December, 2020</a></li><li><a href="./archive-covid-19/21 December, 2020.html">21 December, 2020</a></li><li><a href="./archive-covid-19/20 December, 2020.html">20 December, 2020</a></li><li><a href="./archive-covid-19/19 December, 2020.html">19 December, 2020</a></li><li><a href="./archive-covid-19/18 December, 2020.html">18 December, 2020</a></li><li><a href="./archive-covid-19/17 December, 2020.html">17 December, 2020</a></li><li><a href="./archive-covid-19/16 December, 2020.html">16 December, 2020</a></li><li><a href="./archive-covid-19/15 December, 2020.html">15 December, 2020</a></li><li><a href="./archive-covid-19/14 December, 2020.html">14 December, 2020</a></li><li><a href="./archive-covid-19/13 December, 2020.html">13 December, 2020</a></li><li><a href="./archive-covid-19/12 December, 2020.html">12 December, 2020</a></li><li><a href="./archive-covid-19/11 December, 2020.html">11 December, 2020</a></li><li><a href="./archive-covid-19/10 December, 2020.html">10 December, 2020</a></li><li><a href="./archive-covid-19/09 December, 2020.html">09 December, 2020</a></li><li><a href="./archive-covid-19/08 December, 2020.html">08 December, 2020</a></li><li><a href="./archive-covid-19/07 December, 2020.html">07 December, 2020</a></li><li><a href="./archive-covid-19/06 December, 2020.html">06 December, 2020</a></li><li><a href="./archive-covid-19/05 December, 2020.html">05 December, 2020</a></li><li><a href="./archive-covid-19/04 December, 2020.html">04 December, 2020</a></li><li><a href="./archive-covid-19/03 December, 2020.html">03 December, 2020</a></li><li><a href="./archive-covid-19/02 December, 2020.html">02 December, 2020</a></li><li><a href="./archive-covid-19/01 December, 2020.html">01 December, 2020</a></li><li><a href="./archive-covid-19/30 November, 2020.html">30 November, 2020</a></li><li><a href="./archive-covid-19/29 November, 2020.html">29 November, 2020</a></li><li><a href="./archive-covid-19/28 November, 2020.html">28 November, 2020</a></li><li><a href="./archive-covid-19/27 November, 2020.html">27 November, 2020</a></li><li><a href="./archive-covid-19/26 November, 2020.html">26 November, 2020</a></li><li><a href="./archive-covid-19/25 November, 2020.html">25 November, 2020</a></li><li><a href="./archive-covid-19/24 November, 2020.html">24 November, 2020</a></li><li><a href="./archive-covid-19/23 November, 2020.html">23 November, 2020</a></li><li><a href="./archive-covid-19/22 November, 2020.html">22 November, 2020</a></li><li><a href="./archive-covid-19/21 November, 2020.html">21 November, 2020</a></li><li><a href="./archive-covid-19/20 November, 2020.html">20 November, 2020</a></li><li><a href="./archive-covid-19/19 November, 2020.html">19 November, 2020</a></li><li><a href="./archive-covid-19/18 November, 2020.html">18 November, 2020</a></li><li><a href="./archive-covid-19/17 November, 2020.html">17 November, 2020</a></li><li><a href="./archive-covid-19/16 November, 2020.html">16 November, 2020</a></li><li><a href="./archive-covid-19/15 November, 2020.html">15 November, 2020</a></li><li><a href="./archive-covid-19/14 November, 2020.html">14 November, 2020</a></li><li><a href="./archive-covid-19/13 November, 2020.html">13 November, 2020</a></li><li><a href="./archive-covid-19/12 November, 2020.html">12 November, 2020</a></li><li><a href="./archive-covid-19/11 November, 2020.html">11 November, 2020</a></li>
</ul>
</body></html>